

## Risk Factors Comparison 2025-03-26 to 2024-02-29 Form: 10-K

Legend: **New Text** ~~Removed Text~~ Unchanged Text **Moved Text Section**

**Our obligations under** You should carefully consider the risks described below together with the other -- **the convertible note information set forth in this report**, which could materially affect **and any additional convertible notes issued pursuant to the October 2024 securities purchase agreement, and the related transaction documents, are secured by a security interest in all of our bank** business, financial condition and future results. The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and operating results. Risk Factors Related to Our Business We have a history of operating losses and expect to incur significant losses in the future. We have had substantial losses since our inception. We cannot assure you that we will ever become or remain profitable. ● As of December 31, 2023, we had an **and** accumulated deficit of \$ 765. 4 million. ● We had an accumulated deficit of \$ 586. 2 million from inception through December 31, 2020, a net loss of \$ 43. 2 million in 2021, a net loss of \$ 53. 1 million in 2022, and a net loss of \$ 82. 8 million in 2023. The likelihood of our success must be considered in light of the expenses, difficulties and delays frequently encountered by companies formed to develop and commercialize new technologies. In particular, our operations to date have focused primarily on research and development of our LBS technology system, including products built around that technology such as our automotive lidar sensor, and development of demonstration units. We are unable to accurately estimate future revenues and operating expenses based upon historical performance. We cannot be certain that we will succeed in obtaining development revenue or commercializing our technology or products at scale. In light of these factors, we expect to continue to incur significant losses and negative cash flow at least through 2024 and likely thereafter. There is significant risk that we will not achieve positive cash flow at any time in the future. We will require additional capital to fund our operations at the level necessary to implement our business plan. Raising additional capital will dilute the value of current shareholders' investment in us. Based on our current operating plan, we anticipate that we have sufficient cash and cash equivalents to fund our operations for at least the next 12 months. We will, however, require additional capital to fund our operating plan past that time. We will seek to obtain additional capital through the issuance of equity or debt securities **accounts**, development revenue, product sales and / or licensing activities. There can be no **now owned** assurance that any such efforts to obtain additional capital would be successful. We are currently focused on developing and commercializing our automotive lidar solution. This involves introducing new technologies into an **and hereafter** emerging market which creates **created** significant uncertainty about our **or acquired** ability to accurately project the amounts and timing of revenue, costs and cash flows. Our capital requirements will depend on many factors, including, but not limited to, the commercial success of our technologies, the rate at which OEMs introduce systems incorporating our products and technologies and the market acceptance and competitive position of such systems. Our expenses have increased significantly as a result of the January 2023 Ibeo acquisition and related headcount increase. If revenues continue to be less than we anticipate, if the mix of revenues and the associated margins vary from anticipated amounts, or if expenses exceed the amounts budgeted, we may require additional capital earlier than expected to fund our operations. In addition, our operating plan provides for the development of strategic relationships with suppliers of components, products and systems, and equipment manufacturers that may require additional investments by us. Additional capital may not be available to us or, if available, may not be available on terms acceptable to us or on a timely basis. Raising additional capital may involve issuing securities with rights and preferences that are senior to our common stock and may dilute the value of our current shareholders' investment in us. If adequate capital resources are not available on a timely basis, we may consider limiting our operations substantially and we may be unable to continue as a going concern. This limitation of operations could include reducing investments in our research and development projects, staff, operating costs, and capital expenditures which could jeopardize our ability to achieve our business goals or satisfy our customer requirements. Risks Related to our Financial Statements and Results Our revenue is generated from a small number of customers, and losing a significant customer will have a negative impact on our revenue. In 2023, one commercial customer, Customer A accounted for \$ 4. 6 million in revenue, representing 63 % of our total revenue, a second commercial customer accounted for \$ 0. 8 million in revenue, representing 11 % of our total revenue and a third commercial customer accounted for \$ 0. 4 million in revenue, representing 5 % of our total revenue. In 2022, Customer A accounted for \$ 0. 7 million in revenue, representing 100 % of our total revenue. No revenue was recognized from this customer during the second half of 2022 or for the first three quarters of 2023 as no shipments of our components were reported by the customer during that period. In 2021, Customer A accounted for \$ 2. 5 million in revenue, representing 100 % of our total revenue. Subsequent to fiscal year 2023, we do not expect to recognize further revenue from Customer A, which will negatively affect our future revenue. We have, in the past, identified a material weakness in our internal controls. In the second quarter of 2021, we identified a material weakness in the controls that support our determination of the grant date of equity awards. If we identify further material weaknesses in our internal controls, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting obligations. Any such failure could cause investors to lose confidence in the accuracy of our financial reports, harm our reputation and adversely affect the market price of our common stock. The audit of our internal controls over financial reporting for fiscal year 2024 will include controls of our subsidiary, MicroVision GmbH, which became a significant subsidiary upon the closing of our acquisition of assets from Ibeo in 2023. Accordingly, our internal control environment will become more complex and, therefore, the risk of a material weakness in internal controls will be higher. Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future, and as a result,

investors in our common stock could incur substantial losses. Our stock price has fluctuated significantly in the past, has recently been volatile, and may be volatile in the future. Over the 52-week period ending February 26, 2024, our common stock has traded at a low of \$ 1.82 and a high of \$ 8.20. We may continue to experience sustained depression or substantial volatility in our stock price in the foreseeable future unrelated to our operating performance or prospects. For the fiscal year ended December 31, 2023, we incurred a loss per share of \$ (0.45). As a result of this volatility, **if we default** investors may experience losses on their investment in our common stock. The market price **obligations under the convertible note, for, or any additional convertible notes, the collateral agent on behalf of the holder could foreclose on the security interests and liquidate some or all of** our **bank and securities accounts** common stock may be influenced by many factors, **which would harm** including the following: • investor reaction to our business strategy; • the success of competitive products or technologies; • strategic developments; • the timing and results of our development and commercialization efforts with respect to our lidar sensors and ADAS solutions; • changes in regulatory or industry standards applicable to our technologies; • variations in our or our competitors' financial and operating results; • developments concerning our collaborations or partners; • developments or disputes with any third parties that supply, manufacture, sell or market any of our products; • developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technology; • actual or perceived defects in any of our products, if commercialized, and any related product liability claims; • our ability or inability to raise additional capital and the terms on which we raise it; • declines in the market prices of stocks generally; • trading volume of our common stock; • sales of our common stock by us or our stockholders; • general economic, industry and market conditions; and • the effects of other events or factors, including war, terrorism and other international conflicts, public health issues including health epidemics or pandemics, such as the COVID-19 outbreak, and natural disasters such as fire, hurricanes, earthquakes, tornados or other adverse weather and climate conditions, whether occurring in the United States or elsewhere. Since the price of our common stock has fluctuated in the past, has suffered recent declines and may be volatile in the future, investors in our common stock could incur substantial losses. In the past, following periods of volatility in the market, securities class action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management's attention and resources, which could materially and adversely affect our business, financial condition, **and** results of operations and **could require us to reduce** growth prospects. There can be no guarantee that our **or** stock price will remain at current levels or that future sales of our common stock will not be at prices lower than those sold to investors. Additionally, securities of certain companies have in the past few years experienced significant and extreme volatility in stock price due to short sellers of shares of common stock, known as a "short squeeze." These short squeezes have caused extreme volatility in both the stock prices of those companies and in the market, and have led to the price per share of those companies to trade at a significantly inflated rate that is disconnected from the underlying value of the company. Many investors who have purchased shares in those companies at an inflated rate face the risk of losing a significant portion of their original investment, as in many cases **cease operations** the price per share has declined steadily as interest in those stocks have abated. There can be no assurance that our shares will not be subject to a short squeeze in the future, and investors may lose a significant portion or all **or part** of their **your** investment if they purchase our shares at a rate that is significantly disconnected from our underlying value. If we are unable to maintain our listing on The Nasdaq Global Market, it could become more difficult to sell our stock in the public market. Our common stock is listed on The Nasdaq Global Market. To maintain our listing on this market, we must meet Nasdaq's listing maintenance standards. If we are unable to continue to meet Nasdaq's listing maintenance standards for any reason, our common stock could be delisted from The Nasdaq Global Market. If our common stock were delisted, we may seek to list our common stock on The Nasdaq Capital Market, the NYSE American or on a regional stock exchange or, if one or more broker-dealer market makers comply with applicable requirements, the over-the-counter (OTC) market. Listing on such other market or exchange could reduce the liquidity of our common stock. If our common stock were to trade in the OTC market, an investor would find it more difficult to dispose of, or to obtain accurate quotations for the price of, the common stock. A delisting from The Nasdaq Global Market and failure to obtain listing on another market or exchange would subject our common stock to so-called penny stock rules that impose additional sales practice and market-making requirements on broker-dealers who sell or make a market in such securities. Consequently, removal from The Nasdaq Global Market and failure to obtain listing on another market or exchange could affect the ability or willingness of broker-dealers to sell or make a market in our common stock and the ability of purchasers of our common stock to sell their securities in the secondary market. On February 26, 2024, the closing price of our common stock was \$ 2.09 per share. Our lack of financial resources relative to our competitors may limit our revenues, potential profits, overall market share or value. Our products and solutions compete with other pureplay lidar developers, many of which have recently gone public through de-SPAC transactions and therefore have substantially greater financial resources than we have. We also face competition from OEMs and Tier 1 suppliers that have internally developed lidar sensors. All of these OEMs and Tier 1s are significantly larger, more well-resourced, have long operating histories and enjoy relevant brand recognition. Because of their greater resources, our competitors may develop or commercialize products more quickly than us and have access to more entrenched sales channels. This imbalance in financial resources and access could result for us in reduced revenues, lower margins or loss of market share, any of which could reduce the value of our business. Additionally, for a variety of reasons, customers may choose to purchase from suppliers that have substantially greater financial or other resources than we have. Risks Related to Our Operations Difficulty in qualifying a contract manufacturer, Tier 1 partner, or foundry for our products, or experiencing **changes-challenges** in our supply chain, could cause delays that may result in lost future revenues and damaged customer relationships. Historically, we have relied on single or limited-source suppliers to manufacture our products. Establishing and maintaining a relationship with a contract manufacturer, automotive Tier 1 partner, or foundry is a time-consuming process, as our unique technologies may require significant manufacturing process adaptation to achieve full manufacturing capacity. To the extent that we are not able to **maintain our existing or** establish or **maintain a new** relationship

with a contract manufacturer, Tier 1 partner, or foundry in a timely manner or at prices or on other terms that are acceptable to us, we may be unable to meet contract or production milestones. Moreover, changes **or challenges** in our supply chain could result in increased cost and **delay delays** and subject us to risks and uncertainties regarding, but not limited to, product warranty, product liability and quality control standards. The loss of any single or limited- source supplier, the failure of any of these suppliers to perform as expected or the disruption in the supply chain of components from these suppliers could cause significant delays in product deliveries, which could result in lost future revenues and damaged customer relationships. Historically, we have been dependent on third parties to develop, manufacture, sell and market products incorporating our technology. Our business strategy for commercializing our technology in products has historically included entering into development, manufacturing, licensing, sales and marketing arrangements with OEMs, ODMs and other third parties. These arrangements reduce our level of control over production and distribution and may subject us to risks and uncertainties regarding, but not limited to, product warranty, product liability and quality control standards. We cannot be certain that we will be able to negotiate arrangements on acceptable terms, if at all, or that these arrangements will be successful in yielding commercially viable products. If we cannot establish or maintain these arrangements, we would require additional capital to undertake such activities on our own and would require extensive manufacturing, sales and marketing expertise that we do not currently possess and that may be difficult to obtain. In addition, we could encounter significant delays in introducing our products and technology or find that the development, manufacture or sale of products incorporating our technology would not be feasible. To the extent that we enter into development, manufacturing, licensing, sales and marketing or other arrangements, our revenues will depend upon the performance of third parties. We cannot be certain that any such arrangements will be successful. We could face lawsuits related to our use of LBS technology or other technologies, which would be costly, and any adverse outcome could limit our ability to commercialize our **technology technologies** or products. We are aware of several patents held by third parties that relate to certain aspects of light scanning displays, 3D sensing products, and other technologies that are core to our sensor hardware. These patents could be used as a basis to challenge the validity, limit the scope or limit our ability to obtain additional or broader patent rights of our patents. A successful challenge to the validity of our patents could limit our ability to commercialize our technology or products incorporating our LBS **or other** technology and, consequently, materially reduce our ability to generate revenues. Moreover, we cannot be certain that patent holders or other third parties will not claim infringement by us with respect to current and future technology. Because U. S. patent applications are held and examined in secrecy, it is also possible that presently pending U. S. applications could eventually be issued with claims that could be infringed by our products or our technology. The defense and prosecution of a patent suit would be costly and time-consuming, even if the outcome were ultimately favorable to us. An adverse outcome in the defense of a patent suit could subject us to significant costs, require others and us to cease selling products incorporating our technology, require us to cease licensing our technology or require disputed rights to be licensed from third parties. Such licenses, if available, would increase our operating expenses. Moreover, if claims of infringement are asserted against our future co- development partners or customers, those partners or customers may seek indemnification from us for any damages or expenses they incur. If we fail to manage expansion effectively, our revenue and expenses could be adversely affected. Our ability to successfully offer products **and solutions** incorporating our technologies and implement our business plan in a rapidly evolving market requires an effective planning and management process. The growth in business and relationships with customers and other third parties has placed, and will continue to place, a significant strain on our management systems and resources. We will need to continue to improve our financial and managerial controls, reporting systems and procedures, and will need to continue to train and manage our **workforce work force**. We continue to strengthen our compliance programs, including our compliance programs related to product certifications (in particular, certifications applicable to the automotive market), export controls, privacy **and**, cybersecurity, and anti- corruption. We may not be able to implement improvements in an efficient or timely manner and may discover deficiencies in existing controls, programs, systems and procedures, which could have an adverse effect on our business, reputation and financial results. We target customers that are large companies with substantial negotiating power and potentially competitive internal solutions; if we are unable to sell our products to these customers, our prospects will be adversely affected. Our potential customers, **including industrial and** automotive OEMs **in particular**, are large, multinational companies with substantial negotiating power relative to us and, in some instances, may have internal solutions that are competitive to our products. These large, multinational companies also have significant resources, which may allow them to acquire or develop competitive technologies either independently or in partnership with others. Accordingly, even after investing significant resources to develop a product, we may not secure a series production award or, even after securing a series production award, may not be able to commercialize a product on profitable terms. If our products are not selected by these large companies or if these companies develop or acquire competitive technology or negotiate terms that are disadvantageous to us, it will have an adverse effect on our business prospects. Our technology and products may be subject to environmental, health and safety regulations that could increase our development and production costs. Our **technology technologies** and products could become subject to environmental, health and safety regulations or amendments that could negatively impact our ability to commercialize our **technology technologies** and products. Compliance with any such current or new regulations would likely increase the cost to develop and commercialize products, and violations may result in fines, penalties or suspension of production. If we become subject to any environmental, health, or safety laws or regulations that require us to cease or significantly change our operations to comply, our business, financial condition and operating results could be adversely affected. Our operating results may be adversely impacted by worldwide political and economic uncertainties and specific conditions in the markets we address. At various times in our history, including **currently and** in the recent past, general worldwide economic conditions have experienced downturns due to slower economic activity, concerns about inflation, increased energy costs, decreased consumer confidence, reduced corporate profits and capital spending, and adverse business conditions. Any continuation or worsening of global economic and financial conditions could materially adversely affect: (i) our

ability to raise, or the cost of, needed capital, (ii) demand for our current and future products, and (iii) our ability to commercialize products. Additionally, the ~~outbreaks~~ **outbreak** of wars or infectious diseases, as recently experienced, may cause an unexpected deterioration in economic conditions. We cannot predict the timing, strength, or duration of any economic slowdown or subsequent economic recovery, worldwide, regionally or in the **industrial, automotive or technology industries sectors**. Because **a significant proportion of our company is outside of the U. S. and we utilize** ~~have recently expanded and plan to continue expanding our international operations and using~~ foreign suppliers and manufacturers, our operating results could be harmed by economic, political, regulatory and other factors in foreign countries. During 2021, we established an office in Germany and on January 31, 2023, we completed our acquisition of certain assets of Ibeo, with the result that we now have more employees and operations in Germany than in the U. S. In addition, we currently use foreign suppliers and partners and plan to continue to do so to manufacture current and future components and products, where appropriate. These international operations are subject to inherent risks, which may adversely affect us, including, but not limited to: • Political and economic instability, international terrorism and the outbreak of war, such as **the Russia Russian** 's invasion and continuing war against Ukraine and the ongoing conflict in **Gaza the Middle East**; • High levels of inflation, as has historically been the case in a number of countries in Asia; • Burdens and costs of compliance with a variety of foreign laws, regulations and sanctions; • Foreign taxes and duties; • ~~Changes~~ **Significant instability** in tariff rates or other trade, tax or monetary policies; • Changes or volatility in currency exchange rates and interest rates; • Global or regional health crises **and**, such as ~~COVID-19 or other~~ epidemics; and • Disruptions in global supply chains. We have recently **made** and may in the future make acquisitions. If we fail to successfully select, execute or integrate our acquisitions, then our business, results of operations and financial condition could be materially adversely affected. On December 1, 2022, we entered into an Asset Purchase Agreement to acquire certain assets from Ibeo Automotive Systems GmbH. We expended significant management time and effort, as well as capital, identifying, evaluating, negotiating, and executing this transaction and, since the closing of the acquisition on January 31, 2023, we have invested additional time and capital working to integrate our new Hamburg- and Detroit- based teams and operations. We cannot guarantee that these integration efforts will be successful, that the goals of the acquisition will be realized, or that the increase to our operating expenses or cash requirements will be manageable. **During the first half of 2024, we downsized our Germany operations.** In the future, we may again undertake acquisitions to add new products and technologies, acquire talent, gain new sales channels or enter into new markets or sales territories. In addition to possible stockholder approval, we may need approvals and licenses from relevant government authorities for the acquisitions and to comply with any applicable laws and regulations, which could result in increased delay and costs, and may disrupt our business strategy if we fail to do so. Furthermore, acquisitions and the subsequent integration of new assets, businesses, key personnel, customers, vendors and suppliers require significant attention from our management and could result in a diversion of resources from our existing business, which in turn could have an adverse effect on our operations. Acquired assets or businesses may not generate the financial results we expect. Acquisitions could result in the use of substantial amounts of cash, potentially dilutive issuances of equity securities, the occurrence of significant goodwill impairment charges, amortization expenses for other intangible assets, and exposure to potential unknown liabilities of the acquired business. Moreover, the costs of identifying and consummating acquisitions may be significant. Before our acquisition of assets from Ibeo, we had no experience with acquisitions or the integration of acquired technology and personnel. Failure to successfully identify, complete, manage, and integrate acquisitions could materially and adversely affect our business, financial condition, and results of operations and could cause our stock price to decline. Our suppliers' or manufacturing partners' facilities could be damaged or disrupted by a natural disaster or labor strike, either of which would materially affect our financial position, results of operations and cash flows. A major catastrophe, such as an earthquake, monsoon, **or flood**; ~~infectious disease including outbreak, such as~~ the COVID- 19 virus; ~~or other natural disaster disasters~~, labor ~~strike strikes~~, or work ~~stoppage stoppages~~ at our suppliers' or manufacturers partners' facilities or our customers, could result in a prolonged interruption of our business. A disruption resulting from any one of these events could cause significant delays in product shipments and the loss of sales and customers, which could have a material adverse effect on our financial condition, results of operations, and cash flows. If we are unable to obtain effective intellectual property protection for our products, processes and **technology technologies**, we may be unable to compete with other companies. Intellectual property protection for our products, processes and **technology technologies** is important and uncertain. If we do not obtain effective intellectual property protection for our products, processes and **technology technologies**, we may be subject to increased competition. Our commercial success will depend, in part, on our ability to maintain the proprietary nature of our key technologies by securing valid and enforceable patents and effectively maintaining unpatented **technology technologies** as trade secrets. We protect our proprietary **technology technologies** by seeking to obtain United States and foreign patents in our name, or licenses to third party patents, related to proprietary **technology technologies**, inventions, and improvements that may be important to the development of our business. However, our patent position involves complex legal and factual questions. The standards that the United States Patent and Trademark Office and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. Additionally, the scope of patents is subject to interpretation by courts and their validity can be subject to challenges and defenses, including challenges and defenses based on the existence of prior art. Consequently, we cannot be certain as to the extent to which we will be able to obtain patents for our new products and **technology technologies** or the extent to which the patents that we already own, protect our products and **technology technologies**. Reduction in scope of protection or invalidation of our licensed or owned patents, or our inability to obtain new patents, may enable other companies to develop products that compete directly with ours on the basis of the same or similar **technology technologies**. We also rely on the law of trade secrets to protect unpatented know- how and **technology technologies** to maintain our competitive position. We try to protect this know- how and **our technology technologies** by limiting access to the trade secrets to those of our employees, contractors and partners, with a need- to- know such information and by entering into confidentiality agreements with parties that have access to it, such as our employees, consultants and

business partners. Any of these parties could breach the agreements and disclose our trade secrets or confidential information, or our competitors might learn of the information in some other way. If any trade secret not protected by a patent were to be disclosed to or independently developed by a competitor, our competitive position could be negatively affected. We could be subject to significant product liability claims that could be time-consuming and costly, divert management attention and adversely affect our ability to obtain and maintain insurance coverage. We could be subject to product liability claims if any of the product applications are alleged to be defective or cause harmful effects. For example, because some of the scanning modules incorporating our LBS technology could scan a low power beam of colored light into the user's eye, the testing, manufacture, marketing and sale of these products involve an inherent risk that product liability claims will be asserted against us. Additionally, any misuse of our **technology-technologies** or products incorporating our **technology-technologies** by end users or third parties that obtain access to our **technology-technologies**, could result in negative publicity and could harm our brand and reputation. Product liability claims or other claims related to our products or our **technology-technologies**, regardless of their outcome, could require us to spend significant time and money in litigation, divert management time and attention, require us to pay significant damages, harm our reputation or hinder acceptance of our products. Any successful product liability claim may prevent us from obtaining adequate product liability insurance in the future on commercially desirable or reasonable terms. An inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or inhibit the commercialization of our products and **technology-technologies**. Our operations could be adversely impacted by information technology system failures, network disruptions, or **cyber-security-cybersecurity** incidents. We rely on information technology systems to process, transmit, store, and protect electronic data between our employees, customers, manufacturing partners and suppliers. Our systems and the third parties we rely on for related services are vulnerable to actual or attempted cybersecurity incidents, such as attacks by hackers, acts of vandalism, malware, social engineering, denial or degradation of service attacks, computer viruses, software bugs or vulnerabilities, supply chain attacks, phishing attacks, ransomware attacks, misplaced or lost data, human errors, malicious insiders or other similar events. Such systems are also susceptible to other disruptions due to events beyond our control, including, but are not limited to, natural disasters, power loss, and telecommunications failures. Our system redundancy may be inadequate and our disaster recovery planning may be ineffective or insufficient to account for all eventualities. As security incidents have become more prevalent across industries we will need to continually examine, modify and update our systems. These updates or improvements may require implementation costs. In addition, we may not be able to monitor and react to all developments in a timely manner. The measures we do adopt may prove ineffective. Any failure, or perceived failure, by us to comply with current and future regulatory or customer-driven privacy, data protection, and information security requirements, or to prevent or mitigate cyber incidents, could harm our business and expose us to potential litigation, liability, remediation costs, investigation costs, loss of revenue, damage to our reputation and loss of customers. While we maintain insurance coverage to address certain aspects of cyber risks, such insurance coverage may be insufficient to cover all losses or all claims that may arise, should such an event occur. We, and certain of our third-party vendors, collect and store personal information in connection with human resources operations and other aspects of our business. While we obtain assurances that any third parties we provide data to will protect this information and, where we believe appropriate, monitor the protections employed by these third parties, there is a risk the confidentiality of data held by us or by third parties may be compromised and expose us to liability for such breach. Loss of any of our key personnel **or inability to attract new personnel** could have a negative effect on the operation of our business. Our success depends on our executive officers and other key personnel and on **the-our** ability to attract and retain qualified new personnel. Achievement of our business objectives will require substantial additional expertise in the areas of sales and marketing, research and product development and manufacturing. Competition for qualified personnel in these fields is intense, and the inability to attract and retain additional highly skilled personnel, or the loss of key personnel, could hinder our ability to compete effectively in the automotive or technology markets and adversely affect our business strategy execution and results of operations. Risks Related to Development for the **Industrial and Automotive Industry-Markets We invest significant time and resources seeking OEM selection of our products and solutions.** If our products and solutions are not selected for inclusion in ADAS systems by automotive OEMs or automotive Tier 1 suppliers **after incurring substantial expenditures in these efforts**, our future **business prospects, results of operations, and financial condition** will be materially and adversely affected. Automotive OEMs and Tier 1 suppliers design and develop ADAS technology over several years, undertaking extensive testing and qualification processes prior to selecting a product such as our lidar sensors and software for use in a particular system, product or vehicle model because such products will function as part of a larger system or platform and must meet certain other specifications. We have invested and will continue to invest significant time and resources to have our products considered and possibly selected by OEMs or Tier 1 suppliers for use in a particular system, product or vehicle model, which is known as a "series production win" or a "series production award." In the case of ADAS technology, a series production award would mean that our lidar sensor and / or ADAS solution had been selected for use in a particular vehicle model. However, if we are unable to achieve a series production award with respect to a particular vehicle model, we may not have an opportunity to supply our products to the automotive OEM for that vehicle model for a period of many years. In many cases, this period can be as long as five to seven or more years. If our products are not selected by an automotive OEM or our suppliers for one vehicle model or if our products are not successful in that vehicle model, it is unlikely that our product will be deployed in other vehicle models of that OEM. If we fail to win a significant number of vehicle models from one or more **of** automotive OEMs or their suppliers, our future business prospects **, results of operations, and financial conditions** will be materially and adversely affected. The complexity of our products and the limited visibility into the various environmental and other conditions under which potential customers may use the products could result in unforeseen delays or expenses from undetected defects, errors or reliability issues in hardware or software which could reduce the market adoption of our products, damage our reputation with prospective customers, expose us to product liability and other claims, and adversely affect our

operating costs. Our products are highly technical and complex and require high standards to manufacture and may experience defects, errors or reliability issues at various stages of development **and production**. We may be unable to timely manufacture or release products, or correct problems that have arisen or correct such problems to the customer's satisfaction. Additionally, undetected errors, defects or security vulnerabilities could result in serious injury to the end users or bystanders of technology incorporating our products, inability of customers to commercialize technology incorporating our products, litigation against us, negative publicity and other consequences. These risks are particularly prevalent in the highly competitive ADAS market. These problems may also result in claims, including class actions, against us that could be costly to defend. Our reputation or brand may be damaged as a result of these problems and potential customers may be reluctant to buy our products, which could adversely affect our financial results. Adverse conditions in **particular industrial sectors**, the automotive industry, or the global economy more generally could have adverse effects on our results of operations. While we make our strategic planning decisions based on the assumption that the markets we are targeting will grow, our business is dependent, in large part on, and directly affected by, business cycles and other factors affecting **industrial autonomy**, the global automobile industry, and **the** global economy generally. Automotive production and sales are highly cyclical and depend on general economic conditions and other factors, including consumer spending and preferences, changes in interest rates and credit availability, consumer confidence, fuel costs, fuel availability, environmental impact, governmental incentives and regulatory requirements, and political volatility, especially in energy-producing countries and growth markets. In addition, automotive production and sales can be affected by our automotive OEM customers' ability to continue operating in response to challenging economic conditions and in response to labor relations issues, regulatory requirements, trade agreements and other factors. The volume of automotive production in North America, Europe and the rest of the world has fluctuated, sometimes significantly, from year to year, and we expect such fluctuations to give rise to fluctuations in the demand for our products. Any significant adverse change in any of these factors may result in a reduction in automotive sales and production by our automotive OEM customers and could have a material adverse effect on our business, results of operations and financial condition. Developments in alternative technology may adversely affect the demand for our lidar technology. Significant developments in alternative technologies, such as cameras and radar, may materially and adversely affect our business prospects in ways we do not currently anticipate. Existing and other camera and radar technologies may emerge as OEMs' preferred alternative to our solution, which would result in the loss of competitiveness of our lidar solution. Our R & D efforts may not be sufficient to adapt to these changes in technology and our solution may not compete effectively with these alternative systems. ADAS features may be delayed in adoption by OEMs, which would negatively impact our **long-term** business prospects. The ADAS market is fast evolving and there is generally a lack of an established regulatory framework. Vehicle regulators globally continue to consider new and enhanced emissions requirements, including electrification, to meet environmental and economic needs as well as pursue new safety standards to address emerging traffic risks. **For instance, in May 2024, the National Highway Traffic Safety Administration, or NHTSA, published a new rule requiring automatic emergency braking systems in U. S. light vehicles and trucks by September 2029, and in December 2024, NHTSA proposed a voluntary program to improve evaluation and oversight of certain vehicles equipped with automated driving systems.** To control new vehicle prices, among other concerns, OEMs may need to dedicate technology and cost additions to new vehicle designs to meet these emissions and safety requirements and postpone the consumer cost pressures of new ADAS features. As additional safety requirements are imposed on vehicle manufacturers, our business prospects may be materially impacted. **Alternatively, if safety regulations in the U. S. were to become less stringent due to oversight reduction efforts, OEMs could be less inclined to pay for higher cost redundant safety systems and technologies, which could negatively impact the uptake of our sensor solutions.** Because the lidar and ADAS markets are rapidly evolving, it is difficult to forecast customer adoption rates, demand, and selling prices for our products and solutions. We are pursuing opportunities in rapidly evolving markets, including technological and regulatory changes, and it is difficult to predict the timing and size of the opportunities. For example, lidar-based ADAS solutions require complex technology and because these automotive systems depend on technology from many companies, commercialization of ADAS products could be delayed or impaired on account of certain technological components of ours or others not being ready to be deployed in vehicles. In addition, the selling prices we are able to ultimately charge in the future for the products we are currently developing may be less than what we currently project. Our future financial performance will depend on our ability to make timely investments in the correct market opportunities. If one or more of these markets experience a shift in prospective customer demand, our products may not compete as effectively, if at all, and they may not be designed into commercialized products. Given the evolving nature of the markets in which we operate, it is difficult to predict customer demand or adoption rates for our products, selling prices or the future growth of our target markets. If demand does not develop or if we cannot accurately forecast it, the size of our markets, inventory requirements or future financial results will be adversely affected. Because **perception solutions involving lidar is are** new in the markets we are seeking to enter, our market forecasts may not materialize as anticipated. Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not materialize as anticipated. These **estimates and** forecasts ~~and estimates~~ relating to the expected size and growth of the markets for lidar-based technology may prove to be inaccurate. Even if these markets experience the forecasted growth we anticipate, we may not grow our business at similar rates, or at all. Our future growth is subject to many factors, including market adoption of our products, which is subject to many risks and uncertainties. Accordingly, we cannot assure you that these forecasts will not be materially inaccurate. ITEM 1B. UNRESOLVED STAFF COMMENTS **None. ITEM 1C. CYBERSECURITY Risk Management and Strategy Our Cybersecurity Processes We continue to strengthen our cybersecurity measures to safeguard our information systems based on industry standards. Our measures include policies to promote internal compliance by our employees, policies and procedures to regularly evaluate the security of our information systems and implementation of third-party products, including intrusion prevention and detection solutions, multifactor identification and anti-virus software, to help detect and protect against**

potential cybersecurity threats. We educate our staff on cybersecurity matters with periodic risk awareness information, phishing awareness campaigns, and training materials. Moreover, given the rapid growth of our global operations in 2023 due to the Ibeo acquisition, and our expectations for near- and long- term strategic growth, our Information Technology, or IT, team is prioritizing enhancements to our response system and continuity plans. A key dimension to the security and effectiveness of our information system is our compliance with standards that are unique to the industries in which we operate. For instance, it is critical that our information system achieves TISAX certification. Established by the German Association of the Automotive Industry, Trusted Information Security Assessment Exchange, or TISAX, is a globally recognized assessment and exchange mechanism for information security in the automotive industry. Automotive OEMs rely on the TISAX label to ensure that suppliers and partners have a solid information security management system in place. To successfully complete the TISAX assessment process in our German and U. S. operations, we are actively evaluating our cybersecurity measures and seeking enhancements, including engaging a third- party auditor and global standardization of our cybersecurity training program, to ensure a comprehensive and robust system. We evaluate our third- party information system providers, as well as any other provider that may have access to our data, for their maturity and reliability, and as a matter of policy we choose to only work with reputable vendors. Risks from Cybersecurity Threats We have not encountered cybersecurity incidents that have materially affected or are reasonably likely to materially affect us, including our operations or financial condition. A cybersecurity incident could be deemed to have a material impact on our operations if it caused a disruption to our ability to function as a global organization, including the interruption of our internal and external communications, public reporting, or management of our operations. Refer to “ Item 1A. Risk Factors ” in this annual report on Form 10-K, including “ Our operations could be adversely impacted by information technology system failures, network disruptions, or cybersecurity breaches, ” for additional discussion about cybersecurity- related risks. Governance Board of Directors and Audit Committee With delegated authority from our Board of Directors and in accordance with its charter, our Audit Committee is charged with the oversight of enterprise risk, including risk related to cybersecurity threats. Our Audit Committee Chair is expected to report regularly to our Board of Directors about our Audit Committee’ s oversight of enterprise risk. Our Audit Committee Chair reports quarterly to our Board of Directors specifically about our cybersecurity incident management and governance. Management, and specifically our Chief Financial Officer, reports quarterly to our Audit Committee on cybersecurity, including initiatives and strategies, and incident reporting and any lessons learned. From time to time, management will also engage in informal discussions with members of the Audit Committee about our cybersecurity practices and risks, including informing our Audit Committee Chair in a timely manner about any cybersecurity incidents that management determines may have a significant impact on our operations or that may trigger any reporting obligations. Our Audit Committee will conduct an annual review of our cybersecurity measures and the effectiveness of our risk management strategies. Management Anubhav Verma, joined MicroVision in 2021 as our Chief Financial Officer. He is an experienced risk management professional and currently oversees the Company’ s accounting and finance strategies, including risk management. Mr. Verma also oversees our IT team and, with regular communication with the team, is responsible for approving the IT budget, hiring of IT personnel, including third- party consultants, and approving cybersecurity processes and other cybersecurity- related matters. Although we do not currently employ a chief information security officer, we are working with an outside consulting firm that is serving in this role and assisting our internal team with the primary responsibility of overseeing our cybersecurity measures and risks. The day- to- day responsibility for assessing, monitoring and managing our cybersecurity risks resides with our IT team. Across the IT team we have employees who have in- depth knowledge and decades of cybersecurity industry experience, including prior experience with developing and overseeing cybersecurity polices and processes for companies required to comply with NIST SP800- 171, cybersecurity standards for companies that store sensitive unclassified information on behalf of the United States government, and former Ibeo employees having experience with TISAX compliance. Yet, we recognize the evolving and increasing threat that cybersecurity will have on our operations. As part of our long- term growth strategy, we expect to establish a dedicated cybersecurity team to oversee our cybersecurity risk management. The IT Team Director regularly meets with the Chief Financial Officer and as appropriate the Chief Executive Officer to discuss cybersecurity risks. This ensures that management is informed about our current cybersecurity measures and aware of any potential risks facing our operations. In the event of a cybersecurity incident, we have put in place a reporting structure to inform the Chief Financial Officer, Chief Executive Officer and General Counsel promptly of any incident so that they may assess the appropriate response to the incident and any reporting concerns that may be triggered by the incident. ITEM 2. PROPERTIES In September 2021, we entered into a lease on approximately 16, 681 square feet of space located in Redmond, Washington that we use primarily for product testing and lab space. The lease provides for an initial term of 128 months that commenced November 1, 2021. In September 2021, we entered into a second lease on approximately 36, 062 square feet of space located in Redmond, Washington that we use primarily for general office space. The lease provides for an initial term of 120 months and commenced on December 1, 2022. In December 2023, we entered into a lease on approximately 60, 000 square feet of space located in Hamburg, Germany that we will use primarily for general office space and product testing. The lease provides for an initial term of 60 months and commenced on November 1, 2024. We believe that our facilities are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional or substitute space will be available to accommodate any such expansion of our operations. For a further description of our leased properties, see Part II, Item 8, Note 10. Leases, of the notes to our consolidated financial statements, which is incorporated by reference in response to this item. ITEM 3. LEGAL PROCEEDINGS We are subject to various claims and pending or threatened lawsuits in the normal course of business. We are not currently

party to any other legal proceedings that management believes are reasonably possible to have a material adverse effect on our financial position, results of operations or cash flows. ITEM 4. MINE SAFETY DISCLOSURES Not applicable.

**ITEM 4A. EXECUTIVE OFFICERS OF THE REGISTRANT** Executive officers are appointed by our Board of Directors and hold office until their successors are elected and duly qualified. The following persons serve as executive officers of MicroVision, Inc.: Sumit Sharma, age 51, was appointed Chief Executive Officer in February 2020 and served as Chief Operating Officer from June 2018 to February 2020, after serving as Vice President of Product Engineering and Operations since February 2017 and Vice President and Senior Director of Operations since September 2015. Prior to MicroVision, from April 2015 to September 2015, he was a Product Development and Operations consultant at BlueMadison Consulting. From November 2013 to March 2015, he was the Senior Director, Advanced Manufacturing Operations and Technology Development at Jawbone. From March 2011 to October 2013, he was the Head of Manufacturing Operations for project GLASS at Google. Mr. Sharma has extensive experience in optics, wearable technology, product development and qualification for automotive industry. Mr. Sharma also has deep experience in global operations and developing strategic partnerships. A patent holder, Mr. Sharma received his baccalaureate degree in engineering from New Jersey Institute of Technology. Anubhav Verma, age 39, was named Senior Vice President, Chief Financial Officer & Treasurer in June 2024, having joined MicroVision in November 2021 as Chief Financial Officer. Prior to MicroVision, from October 2016 to November 2021, he led several growth initiatives including M & A and Capital Market transactions as Senior Vice President Finance of Exela Technologies. From November 2013 to October 2016, he was an Investment Professional of HandsOn Global Management driving end-to-end M & A deals including post-merger integration along with several rounds of capital market financings. From July 2009 to October 2013, he advised several Fortune 500 companies as an Investment Banker at Credit Suisse in their New York and Mumbai offices. Mr. Verma has extensive experience in Mergers and Acquisitions (M & A), Capital Markets and Strategic Finance roles for publicly listed and privately held companies. Mr. Verma received a Bachelor of Technology degree in engineering and a Masters of Technology degree in engineering from the Indian Institute of Technology, Bombay. Drew Markham, age 57, was named Senior Vice President, General Counsel & Secretary, and Head of People Operations in June 2024, having joined MicroVision in June 2021 as Vice President, General Counsel & Secretary. Before joining MicroVision, from January 2017 through June 2021, Ms. Markham was President at Avisé, a social purpose corporation, where she was a legal consultant to publicly traded technology companies. From January 2013 to December 2016, she was Vice President, Deputy General Counsel & Assistant Secretary at RealNetworks, Inc. From June 1999 to December 2012, she was an attorney with Wilson Sonsini Goodrich & Rosati. Ms. Markham received her Juris Doctor degree from the University of Washington School of Law and her Bachelor of Science degree in Accounting from the University of Florida. Glen W. DeVos, age 64, joined MicroVision in March 2025 as Senior Vice President and Chief Technology Officer. Prior to MicroVision, he served in various business leadership and technology roles at Aptiv and its predecessor Delphi Automotive from 1992 to March 2024. From March 2017 to March 2024, he was a Senior Vice President and he served as Chief Technology Officer until January 2023. Also during that time, he served as President of Aptiv's Advanced Safety and User Experience business unit from April 2021 to January 2023 and as President of its Mobility and Services Group from December 2017 to March 2020. Aptiv PLC, an Irish company headquartered in Switzerland with securities traded on the NYSE, is an engineering company focused on mobility and autonomous technologies for the automotive and commercial vehicle industries. Aptiv was spun out of Delphi Automotive in March 2017; Delphi was spun out of GM in 1999.

**PART II. ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES**

**Market Information**  
Our common stock began trading publicly on August 27, 1996. Our common stock trades on The Nasdaq Global Market under the ticker symbol "MVIS." We have never declared or paid cash dividends on our common stock. We currently anticipate that we will retain all future earnings to fund the operations of our business and do not anticipate paying dividends on the common stock in the foreseeable future. As of March 20, 2025, there were approximately 139 holders of record of 245,004,785 shares of common stock outstanding. As many of our shares of common stock are held by brokerages and institutions on behalf of shareholders, we are unable to estimate the total number of beneficial holders of our common stock represented by these record holders.

**Stock Performance Graph** This performance graph shall not be deemed to be "soliciting material" or "filed" or incorporated by reference in future filings with the Securities and Exchange Commission, or subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The following graph shows a comparison from 2019 through 2024 of the cumulative total return for our common stock, the Russell 2000 Index and the Dow Jones US Electronic and Electrical Equipment Index. Our prior annual reports had included cumulative total return from the NASDAQ Electrical Components Index, however it is not included on this graph because the index has been discontinued. The comparisons in the graph are historical and are not intended to forecast or be indicative of possible future performance of our common stock.

**Recent Sales of Unregistered Securities** On November 21, 2023, pursuant to subscription agreements dated as of November 14, 2023, between us and each of the purchasers, we sold in the aggregate 50,761 shares of our common stock, par value \$ 0.001 per share ("Common Stock"), at \$ 1.97 per share, for an aggregate purchase price of approximately \$ 0.1 million. The purchasers consisted of our Chief Executive Officer, Chief Financial Officer, General Counsel and certain members of our Board of Directors. On March 13, 2023, pursuant to a subscription agreement dated as of March 13, 2023, we sold to our Chief Executive Officer 100,000 shares of Common Stock, at \$ 2.14 per share, for an aggregate purchase price of \$ 0.2 million. The sales of our Common Stock described above were each undertaken in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Section 4(a)(2). **ITEM 6. RESERVED** **ITEM 7.**

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**The following discussion of our financial condition and results of operations should be read in conjunction with our audited consolidated financial statements and the related notes included in Part II, Item 8 of this Form 10- K. The following discussion focuses on the results of our operations for the year ended December 31, 2024 compared to the year ended December 31, 2023. Similar discussion of the results of our operations for the year ended December 31, 2023 compared to the year ended December 31, 2022 can be found in " Management's Discussion and Analysis of Financial Condition and Results of Operations " in Part II, Item 7 of our Annual Report on Form 10- K for the year ended December 31, 2023. Overview Currently, our development and commercialization efforts are focused primarily on perception solutions for autonomy and mobility applications, including industrial and automotive perception systems and advanced driver- assistance systems (ADAS), where we can deliver safe mobility at the speed of life. Our integrated solution combines our perception software stack, lidar sensors utilizing our MEMS- based and flash- based technologies, and custom application software targeted for sale to industrial and automotive OEMs, automated warehouse operators, robotic developers, Tier 1 automotive suppliers, other industrial market players, and the military and defense technology companies. Although perception solutions, including industrial and automotive lidar, are our priority now, we have developed solutions for augmented reality (AR), interactive displays, and consumer lidars. In the recent past, our strategy had been to sell AR displays or components, interactive displays, or consumer lidars to original equipment manufacturers (OEMs) and original design manufacturers (ODMs) for incorporation into their products. Previously, we developed AR and helmet- mounted displays for military applications. We have incurred substantial losses since inception and expect to incur a significant loss during the fiscal year ending December 31, 2025. We have funded operations to date primarily through the sale of common stock, convertible preferred stock, warrants, the issuance of convertible debt and, to a lesser extent, from development contract revenues, product sales and licensing activities. In October 2024, we entered into a securities purchase agreement with an institutional investor for the purchase of senior secured convertible notes of up to \$ 75. 0 million. See Part II, Item 8, Note 7. Notes Payable and Derivative Liability. In February 2025, we entered into another securities purchase agreement with the same institutional investor for the issuance and sale of \$ 8. 0 million in shares of common stock, plus warrants to purchase additional shares of common stock for approximately \$ 9. 0 million. See Part II, Item 8, Note 16. Subsequent Events. There can be no assurance that additional capital will be available or that, if available, it will be available on terms acceptable to us on a timely basis. We cannot be certain that we will succeed in commercializing our technology or products. Critical Accounting Policies and Estimates Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that materially affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. We evaluate our estimates on a continuous basis. We base our estimates on historical data, terms of existing contracts, our evaluation of trends in the consumer display and 3D sensing industries, information provided by our current and prospective customers and strategic partners, information available from other outside sources and on various other assumptions we believe to be reasonable under the circumstances. The results form the basis for making judgments regarding the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe the following key accounting policies require significant judgments and estimates used in the preparation of our consolidated financial statements. Business Combination Our business combination is accounted for under the acquisition method. We allocate the fair value of purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The excess of the fair value of the underlying net assets acquired and liabilities assumed over the purchase consideration is included in bargain purchase gain in the Consolidated Statement of Operations. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Intangible Assets Our intangible assets consist of acquired technology from the January 2023 Ibeo asset purchase and purchased patents. The estimated fair value of acquired technology was calculated through the income approach using the multi- period excess earnings and relief from royalty methodologies. The intangible assets are amortized using the straight- line method over their estimated period of benefit, ranging from one to seventeen years. Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying value may not be recoverable. Recoverability of these assets is measured by comparison of their carrying values to the projected undiscounted net cash flows associated with the related intangible assets or group of assets over their remaining lives. Measurement of an impairment loss for our intangible assets is based on the difference between the fair value of the asset and its carrying value. During 2024, we recorded a non- cash impairment charge of \$ 4. 2 million related to our Reference software. See Part II, Item 8, Note 8. Financial Statement Components – Intangible Assets. Share- Based Compensation We issue share- based compensation to employees in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for the share- based awards by recognizing the fair value of share- based compensation expense on a straight- line basis over the service period of the award, net of estimated forfeitures. The fair value of stock options is estimated on the grant date using the Black- Scholes option pricing model. The fair value of RSUs and non- executive PSUs is determined by the closing price of our common stock on the grant date or the period end date for the awards that are being measured by the service inception date. For performance- based awards, expense is recognized when it is probable the performance criteria will be achieved. If the likelihood becomes improbable that the performance criteria will be achieved, the expense is reversed. The fair value of RSUs and PSUs (other than certain executive PSUs) is determined by the closing

price of our common stock on the grant date or the period end date for the awards that are being measured by the service inception date. Executive PSUs issued in 2022 were valued using a Monte Carlo simulation model using the following inputs: stock price, volatility, and risk-free interest rates. Changes in estimated inputs or using other option valuation methods may result in materially different option values and share-based compensation expense. Significant judgment may be required when determining whether a contract contains a lease, the length of the lease term, the allocation of the consideration in a contract between lease and non-lease components, and the determination of the discount rate included in our office lease. We review the underlying objective of each contract, the terms of the contract, and consider our current and future business conditions when making these judgments. We evaluate our financial instruments, specifically, our notes payable, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815, "Derivatives and Hedging". For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the issuance date and is then re-valued at each reporting date, with changes in the fair value reported as an unrealized gain or loss in earnings on the consolidated statements of operations.

**Results of Operations**

	2024	2023	\$ change	% change
Revenue	\$ 4,696	\$ 7,259	(2,563)	(35.3)
Cost of revenue	\$ 7,530	\$ 160.3	\$ 2,772	38.2
Research and development expense	\$ 49,015	\$ 56,707	(\$ 7,692)	(13.6)
Sales, marketing, general and administrative expense	\$ 29,346	\$ 36,689	(\$ 7,343)	(20.0)
Impairment loss on intangible assets	\$ 4,181	\$ -	\$ 4,181	-
Bargain purchase gain, net of tax	\$ -	\$ 1,669	(\$ 1,669)	(100.0)

Revenues are recognized when control of the promised goods or services are transferred to our customers, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. We recognize revenue either at a point in time, or over time, depending upon the characteristics of the individual contract. If control of the deliverable(s) transfers over time, the revenue is recognized in proportion to the transfer of control. If control passes to the customer only upon completion and transfer of the asset, revenue is recognized at the completion of the contract. The decrease in revenue for the year ended December 31, 2024 compared to the same period in 2023 was primarily due to revenue associated with the Microsoft contract partially offset by the sale of sensors to an existing industrial customer for agricultural equipment and service parts, an increase in shipments of MOVIA L sensors to Daimler Truck North America and affiliates as part of their RFQ evaluation process, and increased sales to a second industrial customer. Cost of revenue includes the direct and allocated indirect costs of products and services sold to customers. Direct costs include labor, materials, reserves for estimated warranty expenses, and other costs incurred directly, or charged to us by our contract manufacturers, in the manufacture of these products. Indirect costs include labor, overhead, and other costs associated with operating our manufacturing capabilities. Overhead includes the costs of procuring, inspecting and storing material, facility and other costs, and is allocated to cost of revenue based on the proportion of indirect labor which supported revenue activities. Cost of revenue can fluctuate significantly from period to period, depending on the product mix and volume, the level of overhead expense and the volume of direct material purchased. The increase in cost of revenue for the year ended December 31, 2024 compared to the same period in 2023 was primarily due to inventory write-downs primarily associated with older configurations of the MOVIA L sensors. Research and development expense consists of compensation related costs of employees and contractors engaged in internal research and product development activities, direct material to support development programs, laboratory operations, outsourced development and processing work, and other operating expenses. We assign our research and development resources based on the business opportunity of the available projects, the skill mix of the resources available and the contractual commitments we have made to our customers. We believe that a substantial level of continuing research and development expenses will be required to further develop our scanning technology. The decrease in research and development expense during the year ended December 31, 2024 compared to the same period in 2023 was primarily due to lower salary and benefits expense and non-cash compensation of \$ 11.2 million as a result of 2024 restructuring events (see Part II, Item 8, Note 14. Restructuring Charges), lower depreciation expense of \$ 0.8 million, lower freight costs of \$ 0.2 million, lower direct materials and equipment costs of \$ 0.2 million, and lower travel expenses of \$ 0.2 million. These decreases were partially offset by restructuring charges of \$ 5.4 million, and higher IT and software costs of \$ 0.5 million. Sales, marketing, general and administrative expense includes compensation and support costs for marketing, sales, management and administrative staff, and for other general and administrative costs, including legal and accounting services, consultants and other operating expenses. The decrease in sales, marketing, general and administrative expense during the year ended December 31, 2024 as compared to the same period in 2023 was primarily due to lower salary and benefits expense and non-cash compensation of \$ 4.6 million as a result of 2024 restructuring events (see Part II, Item 8, Note 14. Restructuring Charges), lower professional fees of \$ 1.8 million primarily related to legal and audit fees associated with the acquisition of Ibeo in 2023, lower subcontractor fees of \$ 0.7 million, lower business insurance fees of \$ 0.6 million due to favorable rates obtained, and lower advertising costs of \$ 0.3 million. These decreases were partially offset by restructuring charges of \$ 0.6 million, higher IT and software costs of \$ 0.4 million, higher trade show expense of \$ 0.2 million, and higher building expenses of \$ 0.2 million. Impairment loss on intangible assets includes impairment charges on intangible assets. During the year ended December 31, 2024, management identified impairment indicators related to MOSAIK software. We performed an assessment of projected future cash flows and determined the software was fully impaired, which resulted in a \$ 4.2 million impairment charge. See Part II, Item 8, Note 8. Financial Statement Components for additional discussion.

31, 2023, we recorded a bargain purchase gain related to the acquisition of assets from Ibeo. The bargain purchase gain represents the excess of the fair value of the underlying net assets acquired and liabilities assumed over the purchase consideration paid in the transaction. Interest expense 2024 2023 \$ change % change (In thousands) Interest expense \$ (4, 457) \$ (80) \$ (4, 377) 5, 471. 3 The increase in interest expense during the year ended December 31, 2024 compared to the same period in 2023 relates to \$ 4. 4 million of non- cash interest expense on notes payable that originated in October 2024. See Part II, Item 8, Note 7. Notes Payable and Derivative Liability for additional discussion. Unrealized loss on derivative liability 2024 2023 \$ change % change (In thousands) Unrealized loss on derivative liability \$ (8, 866) \$- \$ (8, 866)- Unrealized loss on derivative liability reflects the revaluation of our derivative liability associated with notes payable as of December 31, 2024. Due to the increase in the fair value of the derivative liability as of December 31, 2024 relative to its initial measurement on October 23, 2024, we recognized an unrealized loss during 2024. See Part II, Item 8, Note 7. Notes Payable and Derivative Liability for additional discussion. Other income (expense), net 2024 2023 \$ change % change (In thousands) Other income \$ 2, 434 \$ 5, 590 \$ (3, 156) (56. 5) The decrease in other income during the year ended December 31, 2024 compared to the same period in 2023 is primarily due to a payment received in 2023 of \$ 3. 0 million as an incentive to terminate our previous building lease. Income Taxes During the years ended December 31, 2024 and 2023, we recognized tax expense of \$ 0. 5 million and \$ 1. 1 million, respectively, mainly related to income in foreign jurisdictions offset, partially offset by a deferred income tax benefit generated by the reduction to a deferred tax liability created as a result of the acquisition of Ibeo in Q2 2023. The change in income tax expense during the year ended December 31, 2024 was largely the result of lower profitability in foreign jurisdictions. As of December 31, 2024, we had net operating loss carryforwards of approximately \$ 498. 0 million for federal income tax reporting purposes. In addition, we have research and development tax credits of \$ 11. 1 million. During 2024, \$ 28. 2 million federal net operating losses and \$ 0. 2 million general business credits expired unused. A majority of the net operating loss carryforwards and research and development credits available to offset future taxable income, if any, will expire in varying amounts from 2025 to 2044, if not previously used. In certain circumstances, as specified in the Internal Revenue Code, a 50 % or more ownership change by certain combinations of our shareholders during any three- year period would result in a limitation on our ability to use a portion of our net operating loss carryforwards. We recognize interest accrued and penalties related to unrecognized tax benefits in tax expense. We did not have any unrecognized tax benefits at December 31, 2024 or at December 31, 2023. Liquidity and Capital Resources We have incurred significant losses since inception. We have funded operations to date primarily through the sale of common stock, convertible preferred stock, warrants, the issuance of convertible debt and, to a lesser extent, from development contract revenues, product sales, and licensing activities. As of December 31, 2024, the Company had \$ 54. 5 million in cash and cash equivalents and \$ 20. 2 million in short- term investment securities, or \$ 74. 7 million total. In February 2025, we raised net proceeds of \$ 7. 8 million through sale of common stock to an existing investor. In addition to cash and cash equivalents, the Company also has potential availability of \$ 143. 6 million comprised of the following: • \$ 113. 6 million availability left on our existing \$ 150. 0 million ATM facility that was put in place in the first quarter of 2024, subject to certain factors including authorized shares available and market conditions, and • \$ 30. 0 million from the remaining commitment pursuant to the Note, subject to certain limitations. See Part II, Item 8, Note 7. Notes Payable and Derivative Liability. In consideration of the above, the Company has total liquidity of \$ 226. 1 million. Pursuant to terms of the Note, we will maintain minimum cash liquidity of \$ 30. 0 million for the duration of the Note term, subject to decreases beginning on May 1, 2025. Based on our current operating plan, we anticipate that we have sufficient cash and cash equivalents to fund our operations for at least the next 12 months. Operating activities Cash used in operating activities totaled \$ 68. 5 million during 2024, compared to \$ 67. 1 million in 2023. During the years ended December 31, 2024 and 2023, we made payments of \$ 1. 9 million and \$ 3. 1 million, respectively, to our contract manufacturing partner in connection with the buildup of MOVIA sensor inventory for direct sales to both automotive and non- automotive customers. Moreover, we expect to make additional minimum payments to this partner totaling approximately \$ 6. 3 million during 2025 and 2026 in line with agreed- upon deliveries. Investing activities During the year ended December 31, 2024, cash provided by investing activities was \$ 2. 7 million compared to \$ 21. 8 million during the same period in 2023. During the year ended December 31, 2024, we purchased short- term investment securities totaling \$ 26. 1 million and sold short- term investment securities totaling \$ 35. 4 million, compared to purchases of \$ 41. 7 million and sales of \$ 76. 7 million in the same period of 2023. During the year ended December 31, 2024, we purchased property and equipment totaling \$ 0. 4 million compared to \$ 2. 0 million in the same period in 2023. During the year ended December 31, 2024, we made payments totaling \$ 6. 3 million related to the acquisition of Ibeo assets compared to \$ 11. 2 million in the same period in 2023. Financing activities Net cash provided by financing activities totaled \$ 72. 9 million during the year ended December 31, 2024, compared to \$ 72. 4 million during the same period of 2023. Proceeds received from stock option exercises totaled \$ 0. 1 million during the year ended December 31, 2024, compared to \$ 0. 3 million during the same period in 2023. Net proceeds from issuance of common stock were \$ 34. 7 million during the year ended December 31, 2024, compared to \$ 72. 3 million during the same period in 2023. In 2024, we received approximately \$ 38. 1 million in net proceeds, inclusive of debt issuance costs, from the issuance of \$ 45. 0 million senior secured convertible notes. See Part II, Item 8. Note 7, Notes Payable and Derivative Liabilities. The following is a list of our financing activities during 2024 and 2023. • In October 2024, we entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) for the purchase of senior secured convertible notes (the “ Note ”) with an institutional investor (the “ Holder ”). The principal amount for the initial note is \$ 45. 0 million, with an option for the Company to issue additional principal in the amount of \$ 30. 0 million of convertible notes to the Holder, subject to certain limitation. We received proceeds, net of all costs, of \$ 38. 1 million. • In March 2024, we entered into a \$ 150. 0 million ATM equity offering agreement with

Deutsche Bank Securities, Inc., Mizuho Securities USA LLC and Craig-Hallum Capital Group LLC (collectively, the “Agents”). Under the agreement, we are able, at our discretion, to offer and sell shares of our common stock having an aggregate value of up to \$ 150. 0 million through or directly to the Agents. As of December 2024, we completed sales under such sales agreement of 23. 3 million shares for net proceeds of \$ 34. 7 million. As of December 31, 2024, we have approximately \$ 113. 6 million available under this sales agreement. • In June 2021, we entered into a \$ 140. 0 million ATM equity offering agreement with Craig-Hallum. Under the agreement we were able, at our discretion, to offer and sell shares of our common stock having an aggregate value of up to \$ 140. 0 million through Craig-Hallum. As of December 31, 2022, we had issued 8. 3 million shares of our common stock for net proceeds of \$ 81. 8 million under this ATM agreement. During the quarter ended March 31, 2023, we issued 5. 0 million shares of our common stock for net proceeds of \$ 12. 5 million under the agreement. The sales agreement was terminated in June 2023. • In June 2023, we entered into a \$ 45. 0 million ATM equity offering agreement with Craig-Hallum. Under the agreement, we were able, at our discretion, to offer and sell shares of our common stock having an aggregate value of up to \$ 45. 0 million through Craig-Hallum. As of June 30, 2023, we had completed sales under such sales agreement, having sold 10. 9 million shares for net proceeds of \$ 43. 9 million. No further shares are available for sales under this agreement. Our capital requirements will depend on many factors, including, but not limited to, the rate at which OEMs and other potential customers introduce products incorporating our technology and the market acceptance and competitive position of such products. Our ability to raise capital will depend on numerous factors, including the following: • Perceptions of our ability to continue as a going concern; • Market acceptance of products incorporating our technology; • Changes in evaluations and recommendations by any securities analysts following our stock or our industry generally; • Announcements by other companies in our industry; • Changes in business or regulatory conditions; • Announcements or implementation by our competitors of technological innovations or new products; • The status of particular development programs and the timing of performance under specific development agreements; • Economic and stock market conditions; • The cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; • Our ability to establish cooperative development or licensing arrangements; • Our authorized shares available for sale; or • Other factors unrelated to our company or industry. If we are successful in establishing OEM co-development arrangements, we may receive full or partial funding for certain non-recurring engineering costs for technology development and / or product development. Nevertheless, we expect our capital requirements to remain high as we expand our activities and operations with the objective of commercializing our technology. Recent Accounting Pronouncements See Note 2, “ Summary of significant accounting policies, ” in the notes to the consolidated financial statements found in Part II, Item 8 of this Form 10-K. **ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK** Interest Rate and Market Liquidity Risks As of December 31, 2024, all of our cash and cash equivalents have variable interest rates; however, we believe our exposure to market and interest rate risks is not material. Due to the generally short-term maturities of our investment securities, we believe that the market risk arising from our holdings of these financial instruments is not significant. We do not believe that inflation has had a material effect on our business, financial condition or results of operations; however, we do anticipate our labor costs to increase as a result of inflationary pressures. Our investment policy generally directs that the investment managers should select investments to achieve the following goals: principal preservation, adequate liquidity, and return. As of December 31, 2024, our cash and cash equivalents are comprised of short-term highly rated (A rated securities and above) money market savings accounts and our short-term investments are comprised of highly rated corporate and government debt securities (A rated securities and above). The values of cash and cash equivalents and investment securities, available-for-sale as of December 31, 2024, are as follows (in thousands): Amount Percent Cash and cash equivalents \$ 54, 486 72. 9 % Less than one year 20, 216 27. 1 % \$ 74, 702 100. 0 % Foreign Exchange Rate Risk Our major contract and collaborative research and development agreements, product sales, and licensing activity payments are currently made in U. S. dollars or Euros. Changes in the relative value of the U. S. dollar to the Euro and other currencies may affect revenue and other operating results as expressed in U. S. dollars. In addition, our international subsidiary financial statements are denominated in Euros. As such, the consolidated financial statements will continue to remain subject to the impact of foreign currency translation as our international operations continue to expand. In the future, we may enter into foreign currency hedges to offset material exposure to currency fluctuations when we can adequately determine the timing and amounts of the exposure. **ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA INDEX TO CONSOLIDATED FINANCIAL STATEMENTS** Page Report of Independent Registered Public Accounting Firm (Moss Adams LLP, Seattle, Washington, PCAOB ID: 659) Consolidated Balance Sheets as of December 31, 2024 and 2023 Consolidated Statements of Operations for the years ended December 31, 2024, 2023 and 2022 Consolidated Statements of Comprehensive Loss for the years ended December 31, 2024, 2023 and 2022 Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2024, 2023 and 2022 Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022 Notes to Consolidated Financial Statements Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of MicroVision, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of MicroVision, Inc. (the “ Company ”) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and schedules (collectively referred to as the “ consolidated financial statements ”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2024 and 2023, and the consolidated results of its operations and its cash flows for each of the three years ended in the period December 31, 2024, in conformity with

accounting principles generally accepted in the United States of America. Basis for Opinion These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U. S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.

**Valuation of Derivative Liability** As described in note 7, the fair value of the derivative liability is determined utilizing a "with and without" method, in which the fair value is calculated as the difference in the fair value of the entire hybrid instrument and the fair value of the instrument excluding the bifurcated derivative features. The fair value of the hybrid instrument is estimated using a binomial lattice model. The fair value of the host contract excluding embedded derivative features is estimated using a debt discounted cash flow model, which assumes that the contract is a debt instrument with only the option to redeem partial principal payments prior to maturity. The estimated fair value of the derivative liability was \$ 14. 6 million as of December 31, 2024. We identified the valuation of derivative liability as a critical audit matter. Performing audit procedures to evaluate the reasonableness of the fair value estimates and underlying inputs and assumptions required especially challenging and subjective auditor judgment and an increased extent of effort, including the need to involve of our valuation professionals. Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming an overall opinion on the consolidated financial statements. Our audit procedures related to the matter included the following, among others:

- Testing management's process used in determining the estimated fair value of the derivative liability by:
- Involving our valuation professionals with specialized skills and knowledge who assisted in evaluating the valuation methodologies and the reasonableness of significant assumptions.
- Testing the mathematical accuracy of management's calculations.
- Testing the completeness, accuracy and reliability of the underlying data used in the estimate, such as historical volatility, stock price, and daily trading volume.

**Impairment of Intangible Assets** As described in notes 2 and 8 to the consolidated financial statements, intangible assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying value may not be recoverable. Recoverability of these assets is measured by comparison of their carrying values to the projected undiscounted net cash flows associated with the related intangible assets or group of assets over their remaining lives. Measurement of an impairment loss for intangible assets is based on the difference between the fair value of the asset and its carrying value. The carrying value of intangible assets was \$ 11. 0 million as of December 31, 2024. We identified the impairment assessment of intangible assets as a critical audit matter. Performing audit procedures to evaluate the significant assumptions used by management when developing the undiscounted cash flows to be generated by the assets required a high degree of auditor judgment, subjectivity and effort when performing and evaluating the results of those procedures.

- Testing management's process for developing the estimated future undiscounted cash flows used in the impairment assessment.
- Evaluating the appropriateness of the undiscounted cash flows model.
- Testing the completeness and accuracy of the underlying data used in the model.
- Evaluating the reasonableness of the significant assumptions used by management related to estimated future undiscounted cash flows.
- Evaluating management's ability to forecast cash flows by comparing actual results to management's historical forecasts.

/ s / Moss Adams Seattle, Washington March 26, 2025 We have served as the Company's auditor since 2012.

Consolidated Balance Sheets (In thousands, except per share data)	2024	2023
<b>Assets</b>		
Current assets		
Cash and cash equivalents	\$ 54, 486	\$ 45, 167
Investment securities, available- for- sale	20, 216	28, 611
Restricted cash, current	261 3, 263	
Accounts receivable, net of allowances	926 949	
Inventory	2, 294 3, 874	
Other current assets	4, 287 4, 890	
Total current assets	82, 470 86, 754	
Property and equipment, net	7, 061 9, 032	
Operating lease right- of- use assets	16, 746 13, 758	
Restricted cash, net of current portion	1, 500 961	
Intangible assets, net	10, 972 17, 235	
Other assets	2, 412 1, 895	
Total assets	\$ 121, 161 \$ 129, 635	
<b>Liabilities and shareholders' equity</b>		
Current liabilities		
Accounts payable	\$ 1, 132 \$ 2, 271	
Accrued liabilities	2, 542 8, 640	
Accrued liability for Ibeo business combination-	6, 300	
Contract liabilities	308 300	
Derivative liability	14, 581-	
Notes payable, current	24, 248-	
Operating lease liabilities, current	2, 682 2, 323	
Other current liabilities	458 669	
Total current liabilities	45, 951 20, 503	
Notes payable, net of current portion	8, 754-	
Operating		

lease liabilities, net of current portion 15, 954 12, 714 Other long- term liabilities 1, 733 614 Total liabilities 72, 392 33, 831 Commitments and contingencies (Note 11)-- Shareholders' equity Preferred stock, par value \$ 0. 001; 25, 000 shares authorized; zero and zero shares issued and outstanding as of December 31, 2024 and 2023-- Common stock, par value \$ 0. 001; 310, 000 shares authorized; 224, 993 and 194, 736 shares issued and outstanding as of December 31, 2024 and 2023, respectively 225 195 Additional paid- in capital 910, 825 860, 765 Accumulated other comprehensive income- 210 Accumulated deficit (862, 281) (765, 366) Total shareholders' equity 48, 769 95, 804 Total liabilities and shareholders' equity \$ 121, 161 \$ 129, 635 The accompanying notes are an integral part of these consolidated financial statements

Consolidated Statements of Operations 2024 2023 2022 Year Ended December 31, 2024 2023 2022 Revenue \$ 4, 696 \$ 7, 259 \$ 664 Cost of revenue 7, 530 2, 772 100 Gross (loss) profit (2, 834) 4, 487 564 Research and development expense 49, 015 56, 707 30, 413 Sales, marketing, general and administrative expense 29, 346 36, 689 24, 041 Impairment loss on intangible assets 4, 181-- Loss (gain) on disposal of fixed assets 143 (34)- Total operating expenses 82, 685 93, 362 54, 454 Loss from operations (85, 519) (88, 875) (53, 890) Bargain purchase gain, net of tax- 1, 669- Interest expense (4, 457) (80) (62) Unrealized loss on derivative liability (8, 866)-- Other income 2, 434 5, 590 861 Net loss before taxes \$ (96, 408) \$ (81, 696) \$ (53, 091) Income tax expense (507) (1, 146)- Net loss \$ (96, 915) \$ (82, 842) \$ (53, 091) Net loss per share- basic and diluted \$ (0. 46) \$ (0. 45) \$ (0. 32) Weighted- average shares outstanding- basic and diluted 209, 510 182, 802 165, 958 The accompanying notes are an integral part of these consolidated financial statements.

Consolidated Statements of Comprehensive Loss (In thousands) 2024 2023 2022 Year Ended December 31, 2024 2023 2022 Net loss \$ (96, 915) \$ (82, 842) \$ (53, 091) Other comprehensive income Unrealized gain (loss) on investment securities, available- for- sale- 153 (108) Unrealized (loss) gain on translation (210) 184- Total comprehensive income (loss) (210) 337 (108) Comprehensive loss \$ (97, 125) \$ (82, 505) \$ (53, 199)

Consolidated Statements of Shareholders' Equity Shares Par value capital income (loss) deficit equity Accumulated Additional other Total Common Stock paid- in comprehensive Accumulated shareholders' Shares Par value capital income (loss) deficit equity Balance at December 31, 2021 164, 363 \$ 164 \$ 742, 042 \$ (19) \$ (629, 433) \$ 112, 754 Share- based compensation expense 1, 294 1 15, 460-- 15, 461 Exercise of options 525 1 725-- 726 Sales of common stock, net 4, 321 5 13, 994-- 13, 999 Net loss---- (53, 091) (53, 091) Other comprehensive loss--- (108)- (108) Balance at December 31, 2022 170, 503 \$ 171 772, 221 \$ (127) \$ (682, 524) \$ 89, 741 Share- based compensation expense 1, 946 2 16, 139-- 16, 141 Exercise of options 191- 175-- 175 Sales of common stock, net 22, 096 22 72, 230-- 72, 252 Net loss---- (82, 842) (82, 842) Other comprehensive income--- 337- 337 Balance at December 31, 2023 194, 736 \$ 195 \$ 860, 765 \$ 210 \$ (765, 366) \$ 95, 804 Balance 194, 736 \$ 195 \$ 860, 765 \$ 210 \$ (765, 366) \$ 95, 804 Share- based compensation expense 4, 537 5 11, 530-- 11, 535 Exercise of options 84- 62-- 62 Sales of common stock, net 23, 291 23 34, 725-- 34, 748 Conversions of notes payable 2, 345 2 3, 743-- 3, 745 Net loss---- (96, 915) (96, 915) Other comprehensive loss--- (210)- (210) Other comprehensive income (loss)--- (210)- (210) Balance at December 31, 2024 224, 993 \$ 225 \$ 910, 825 \$- \$ (862, 281) \$ 48, 769

MicroVision, Inc. Consolidated Statements of Cash Flows 2024 2023 2022 Year Ended December 31, 2024 2023 2022 Cash flows from operating activities Net loss \$ (96, 915) \$ (82, 842) \$ (53, 091) Adjustments to reconcile net loss to net cash used in operations: Depreciation and amortization 6, 920 7, 864 2, 246 Bargain purchase gain, net of tax- (1, 669)- Loss (gain) on disposal of fixed assets 143 (34)- Unrealized loss on derivative liability 8, 866-- Impairment of intangible assets 4, 181-- Impairment of operating lease right- of- use assets 405-- Impairment of property and equipment- 12 64 Inventory write-downs 2, 045 76 87 Amortization of debt discount and issuance costs on notes payable 4, 382-- Share- based compensation expense 11, 535 16, 141 15, 461 Net accretion of premium on short- term investments (951) (1, 275) 21 Change in: Accounts receivable 23 (949)- Inventory (495) (892) (168) Other current and non- current assets 85 (2, 096) (217) Accounts payable (1, 139) 942 (1, 737) Accrued liabilities (6, 098) 6, 571 888 Contract liabilities and other current liabilities (188) (6, 452) (293) Operating lease liabilities (2, 491) (2, 500) (1, 280) Other long- term liabilities 1, 152 13- Net cash used in operating activities (68, 540) (67, 090) (38, 019) Cash flows from investing activities Sales of investment securities 35, 411 76, 700 60, 576 Purchases of investment securities (26, 065) (41, 710) (90, 158) Advance to Ibeo-- (4, 132) Cash paid for Ibeo business combination (6, 300) (11, 233)- Purchases of property and equipment (374) (1, 935) (4, 359) Net cash provided by (used in) investing activities 2, 672 21, 822 (38, 073) Cash flows from financing activities Principal payments under finance leases- (21) (26) Principal payments under notes payable-- (392) Principal proceeds from notes payable, net of debt discount and issuance costs 38, 080-- Proceeds from stock option exercises 62 175 726 Net proceeds from issuance of common stock 34, 748 72, 284 13, 999 Net cash provided by financing activities 72, 890 72, 438 14, 307 Effect of exchange rate changes on cash and cash equivalents and restricted cash (166) 267- Change in cash, cash equivalents, and restricted cash 6, 856 27, 437 (61, 785) Cash, cash equivalents, and restricted cash at beginning of period 49, 391 21, 954 83, 739 Cash, cash equivalents, and restricted cash at end of period \$ 56, 247 \$ 49, 391 \$ 21, 954

Supplemental schedule of non- cash investing and financing activities Common stock issued in conversion of note payable \$ 3, 745 \$- \$- Non- cash additions to property and equipment \$- \$- \$ 764 Amounts issued to escrow for acquisition consideration \$- \$ 6, 300 \$- Acquisition of right- of- use asset \$ 5, 395 \$ 1, 338 \$ 10, 184 Accrued financing fees \$- \$ (32) \$- Foreign currency translation adjustments \$ (210) \$ 184 \$- Unrealized (gain) loss on investment securities, available- for- sale \$- \$ 153 \$ (108) The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of December 31, 2024, 2023 and 2022: 2024 2023 2022 Year Ended December 31, 2024 2023 2022 Cash and cash equivalents \$ 54, 486 \$ 45, 167 \$ 20, 536 Restricted cash, current 261 3, 263- Restricted cash, net of current portion 1, 500 961 1, 418 Cash, cash equivalents and restricted cash \$ 56, 247 \$ 49, 391 \$ 21, 954

Notes to Consolidated Financial Statements 1. DESCRIPTION OF BUSINESS MicroVision, Inc. is committed to driving the global adoption of proprietary products, which leverage deterministic AI at the edge with the Company' s innovative perception and application software running on diverse lidar sensors. The Company' s solutions enable ADAS and

autonomy features for customers in a wide range of industries including robotics, automated warehouse, agriculture, mining, military, and automotive. The Company's deterministic AI at the edge software running on sensors enables intelligent autonomous, active safety, and automation systems which depend on secure, cost-effective and energy-efficient solutions. This software has been developed in close collaboration with automotive customers and the Company is now rapidly expanding with it into new industrial and commercial vehicle sectors. With engineering teams based in Redmond, Washington and Hamburg, Germany, the Company develops and supplies integrated solutions built on the perception software stack, incorporating application software and processing data from differentiated sensor systems. The Company's extensive experience in developing and productizing core lidar hardware and software components, along with expertise in edge computing, positions the Company as a valuable commercial partner capable of delivering high-value, low-power products. The Company has incurred significant losses since inception. Operations to date have been funded primarily through the sale of common stock, convertible preferred stock, warrants, the issuance of convertible debt and, to a lesser extent, from development contract revenues, product sales, and licensing activities. As of December 31, 2024, the Company had total liquidity of \$ 74.7 million including \$ 54.5 million in cash and cash equivalents and \$ 20.2 million in short-term investment securities. In addition, the Company has approximately \$ 113.6 million availability under its current at-the-market ("ATM") facility as of December 31, 2024, subject to certain conditions. On October 23, 2024, the Company issued \$ 45.0 million in senior secured convertible notes for gross proceeds of \$ 41.4 million and has a remaining commitment pursuant to the convertible note facility of \$ 30.0 million, subject to certain limitations (see Note 7. Notes Payable and Derivative Liability). Subsequent to the date of these financial statements, on February 4, 2025, the Company sold shares of common stock and warrants to purchase common stock for net proceeds of approximately \$ 7.8 million. Additionally, subsequent to the date of these financial statements, maturities of the \$ 45.0 million senior secured convertible notes were reduced by \$ 10.6 million (see Note 16. Subsequent Events). To date, total maturities have been reduced by \$ 12.3 million, inclusive of \$ 1.8 million reduced prior to December 31, 2024 (see Note 7. Notes Payable and Derivative Liability). Based on the current operating plan, the Company anticipates having sufficient cash and cash equivalents to fund operations for at least the next 12 months from the issuance of these consolidated financial statements.

## 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### Principles of Consolidation

The consolidated financial statements and accompanying notes include the accounts of the Company and its wholly owned subsidiaries, after elimination of all intercompany balances and transactions. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. These reclassifications had no impact on net loss, shareholders' equity or cash flows, as previously reported.

### Use of Estimates

The preparation of financial statements in conformity with U. S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts therein. The most significant estimates and assumptions relate to business combinations, valuation of intangibles, valuation of derivative liabilities, revenue recognition, inventory valuation, valuation of share-based payments, income taxes, depreciable lives assessment and related disclosure of contingent assets and liabilities. Due to the inherent uncertainty involved, actual results reported in future periods could differ from those estimates.

### Foreign Currency Translation

Foreign currency transaction gains and losses are a result of the effect of exchange rate changes on transactions denominated in currencies other than the functional currency. Realized gains and losses on those foreign currency transactions are included in determining net loss for the period of exchange and are recorded in other income in the consolidated statements of operations.

### Segment Information

The Company determines operating segments based on how the chief operating decision maker ("CODM") manages the business, makes operating decisions around the allocation of resources, and evaluates operating performance. The CODM is the Executive Management team. The Company has determined that it operates in one operating segment and one reportable segment, relating to the sale and servicing of lidar hardware and software, as the CODM regularly reviews financial information presented on a consolidated basis. Financial information regularly reviewed by the CODM includes revenue, income or loss from operations, and net income or loss. Business combinations are accounted for under the acquisition method. As such, the fair value of the Ibeo purchase consideration was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The excess of the fair value of the underlying net assets acquired and liabilities assumed over the purchase consideration was included in bargain purchase gain, net of tax in the consolidated statements of operations. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets.

### Cash and Cash Equivalents and Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three-level fair value inputs hierarchy and requires an entity to maximize the use of observable valuation inputs and minimize the use of unobservable inputs. The Company uses market data, assumptions and risks that market participants would use in measuring the fair value of the asset or liability, including the risks inherent in the inputs and the valuation techniques. Financial instruments include cash and cash equivalents, investment securities, accounts receivable, accounts payable and accrued liabilities. The carrying value of financial instruments approximate fair value due to their short maturities. Cash equivalents are comprised of short-term highly rated (A rated securities and above) money market savings accounts. Short-term investment securities primarily consist of debt securities. The Company has classified its entire investment portfolio as available-for-sale. Available-for-sale securities are stated at fair value with unrealized gains and losses included in other comprehensive income (loss). Dividend and interest income are recognized when earned. Realized gains and losses, if any, are presented separately on the income statement. Restricted Cash Restricted

cash is held in money market savings accounts and serves as collateral for irrevocable letters of credit related to our facility lease agreements. The restricted cash balance as of December 31, 2024 includes \$ 0. 5 million and \$ 0. 2 million of collateral under two letters of credit, issued in connection with lease agreements for the Company's headquarters and general office and lab space, respectively, in Redmond, Washington. The restricted cash balance also includes approximately \$ 1. 0 million for a security deposit associated with a lease agreement for office space in Hamburg, Germany. Inventory consists of raw materials, work in process and finished goods assemblies. Inventory is computed using the first- in, first- out (FIFO) method and is stated at the lower of cost and net realizable value. Management periodically assesses the need to account for obsolescence of inventory and adjusts the carrying value of inventory to its net realizable value when required. Intangible assets consist of acquired technology from the January 2023 Ibeo asset purchase and purchased patents. As part of the Ibeo asset acquisition, two intangible assets were primarily acquired in the form of Perception software and Reference software, with initial useful lives of 15 years and 8 years, respectively. The estimated fair value of acquired technology was calculated through the income approach using the multi- period excess earnings and relief from royalty methodologies. The intangible assets are amortized using the straight- line method over their estimated period of benefit, ranging from one to seventeen years. Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying value may not be recoverable (see Note 8. Financial Statement Components – Intangible Assets for discussion of impairment). Recoverability of these assets is measured by comparison of their carrying values to the projected undiscounted net cash flows associated with the related intangible assets or group of assets over their remaining lives. Measurement of an impairment loss for intangible assets is based on the difference between the fair value of the asset and its carrying value. Property and Equipment Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets (two to five years) using the straight- line method. Property and equipment may include assets related to future product lines. As production needs change, management will periodically assess the remaining estimated useful life of production equipment. If necessary, depreciation on production equipment will be adjusted to reflect the remaining estimated useful life. Leasehold improvements are depreciated over the lesser of the estimated useful life or the lease term. Costs for repairs and maintenance are charged to expense as incurred and expenditures for major improvements are capitalized at cost. Gains or losses on the disposition of assets are reflected in the consolidated statements of operations at the time of disposal. Management assesses all contracts executed to determine whether the agreements contain a lease component. Significant judgment may be required to determine whether a contract contains a lease, the length of the lease term, the allocation of the consideration between lease and non- lease components, and the appropriate discount rate to be applied. Management reviews the underlying objective of each contract, the terms of the contract, and considers current and future business conditions when making these judgments. The Company's lease obligations consist of various office and equipment operating leases. Operating lease assets are recorded under the operating lease right- of- use asset (" ROU ") line item, while liabilities are recorded under the current portion of operating lease liability and operating lease liability, net of current portion line items on the consolidated balance sheets. Operating lease ROU assets and liabilities are recognized upon lease commencement based on the present value of payments over the lease term. For leases which do not provide an implicit rate, the Company's incremental borrowing rate as of the commencement date serves as the discount rate to determine the present value of lease payments. Lease expense from operating leases is recognized on a straight- line basis over the lease term. Notes Payable The Company evaluates all conversion, redemption, and put features contained in its debt instruments to determine if there are any embedded features that require bifurcation as a derivative. The Company accounts for debt as a long- term liability, with the current portion classified as a short- term liability, equal to the amount repayable at maturity, net of any debt discount and issuance costs, within notes payable on the consolidated balance sheets. The debt discount and issuance costs are amortized over the term of the Note, using the effective interest method, as interest expense in the accompanying consolidated statements of operations. Conversions of principal are accounted for in accordance with ASC 470- 20, " Debt with Conversion and Other Options, " with immediate expense of the unamortized discount associated with the converted principal. The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815, " Derivatives and Hedging ". For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the issuance date and is then re- valued at each reporting date, with changes in the fair value reported as an unrealized gain or loss in earnings on the consolidated statements of operations. The Company has elected to classify the entirety of its derivatives in current liabilities. Revenue Recognition The following is a description of principal activities from which the Company generates revenue. Revenues are recognized when control of the promised goods or services are transferred to customers, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company evaluates contracts based on the 5- step model as stated in Topic 606 as follows: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price, and (v) recognize revenue when (or as) performance obligations are satisfied. A contract contains a promise (or promises) to transfer goods or services to a customer. A performance obligation is a promise (or a group of promises) that is distinct, as defined in the revenue standard. The transaction price is the amount of consideration an entity expects to be entitled to from a customer in exchange for providing the goods or services. A number of factors should be considered to determine the transaction price, including whether there is variable consideration, a significant financing component, noncash consideration, or amounts payable to the customer. The determination of variable consideration will require a significant amount of judgment. In estimating the transaction price, the Company will use either the expected value method or the most likely amount method. The transaction price is allocated to the separate performance obligations in

the contract based on relative standalone selling prices. Determining the relative standalone selling price can be challenging when goods or services are not sold on a standalone basis. The revenue standard sets out several methods that can be used to estimate a standalone selling price when one is not directly observable. Allocating discounts and variable consideration must also be considered. Allocating the transaction price can require significant judgement on the Company's part. Revenue is recognized when (or as) the customer obtains control of the good or service / performance obligations are satisfied. Topic 606 provides guidance to help determine if a performance obligation is satisfied at a point in time or over time. Where a performance obligation is satisfied over time, the related revenue is also recognized over time.

**Product Revenue** Product revenue is primarily derived from sales of lidar hardware and systems. While each contract is individually assessed to identify separate performance obligations, a performance obligation generally consists of an individual sensor or sensor system, inclusive of all materials and integrated software. Transaction prices are normally fixed, as the Company does not include variable consideration or the exchange of any other goods as part of the contract. Revenue is recognized upon shipment of the product to the customer, as control and title of the product passes to the customer at the point of shipment. Product sales generally include acceptance provisions, however, as it can be objectively determined that agreed-upon customer specifications have been met prior to shipment, control of the item passes at the time of shipment.

**License and Royalty Revenue** License and royalty revenue consists of revenue from the licensing of various software and intellectual property owned by MicroVision, and any royalties generated from their use in products sold by customers. Software licenses sold are either a license to install and use, whether perpetual or fixed-term, or a license to access the software, which is normally a volume-based license. Revenue from licenses to install is recognized at the point when the customer is granted the ability to install the software, as these licenses represent functional intellectual property with significant standalone functionality. Revenue from licenses to access is recognized over the period of time in which the Company has ongoing obligations under the agreement, as these licenses represent symbolic intellectual property, which exclude significant standalone functionality. Revenue recognized each period is based on the appropriate measure of progress, typically being the number of usage hours consumed. Revenue from sales-based royalties is recognized based on reports provided by customers which identify the number of royalty-bearing products sold or otherwise distributed. For any customers that fail to provide timely reports, management estimates the number of royalty-bearing products sold based on historical sales volume and available forecast data.

**Contract Revenue** Contract revenue in a particular period is dependent upon when the contract is entered into, the value of the contract, and the availability of technical resources to perform work on the contract. Each performance obligation associated with development contracts is identified at contract inception. The contracts generally include product development and customization specified by the customer. For contracts with multiple product development or customization components, each component is evaluated to determine whether it is distinct within the context of the contract and represents a standalone performance obligation. Components which are deemed not distinct at contract inception are combined into a single performance obligation. Development contracts are primarily fixed-fee contracts. Contract revenue is recognized either at a point in time, or over time, depending upon the characteristics of the individual contract. If control of the deliverable (s) passes to the customer over time, the revenue is recognized in proportion to the transfer of control. If control passes to the customer only upon completion and transfer of the asset, revenue is recognized upon completion of the contract. For contracts which include significant customer acceptance provisions, revenue is recognized only upon acceptance of the deliverable (s). If control of deliverables passes to the customer over time, revenue is recognized based on the proportion of total cost expended to the total cost expected to complete the contract performance obligation (defined as the 'input method' under Topic 606). For contracts which require the input method of revenue recognition, the determination of the total cost expected to complete the performance obligation (s) involves significant judgment. Management initially estimates the resources required to complete each relevant performance obligation, and incorporates revisions to hour and cost estimates throughout the course of the contract as necessary.

**Cost of Product Revenue** Cost of product revenue includes the direct and allocated indirect costs of products sold to customers. Direct costs include labor, materials, reserves for estimated warranty expenses, and other costs incurred directly, or charged by contract manufacturers in the manufacture of these products. Indirect costs include labor, manufacturing overhead, and other costs associated with manufacturing activities. Manufacturing overhead includes the costs of procuring, inspecting and storing material, facility and other costs, and is allocated to cost of product revenue based on the proportion of indirect labor which supported production activities. The cost of product revenue can fluctuate significantly from period to period, depending on product mix and volume, the level of manufacturing overhead expense and the volume of direct material purchased. Cost of Contract Revenue Cost of contract revenue includes both direct and allocated indirect costs of performing work on contracts and producing prototype units and evaluation kits. Direct costs include labor, materials and other costs incurred directly in producing prototype units and evaluation kits or performing work on a contract. Indirect costs include labor and other costs associated with research and development and building technical capabilities and capacity. Cost of contract revenue is determined by the level of direct and indirect costs incurred, which can fluctuate substantially from period to period. Manufacturing overhead, which includes the costs of procuring, inspecting and storing material, and facility and depreciation costs, is allocated to inventory, cost of product revenue, cost of contract revenue, and research and development expense based on the level of effort supporting production or research and development activity.

**Concentration of Credit Risk** Financial instruments that potentially subject the Company to a concentration of credit risk are primarily cash, cash equivalents, and investment securities. As of December 31, 2024, cash and cash equivalents are comprised of operating checking accounts and short-term highly rated money market savings accounts. Short-term investments are comprised of highly rated corporate bonds and U. S. Treasury securities. For the year ended December 31, 2024, three customers accounted for 60 %, 13 %, and 10 % of total revenue,

respectively, or \$ 2. 8 million, \$ 0. 6 million, and \$ 0. 5 million of total revenue, respectively. For the same period in 2023, two customers accounted for 63 % and 11 % of total revenue, respectively, or \$ 4. 6 million and \$ 0. 8 million, respectively. As of December 31, 2024, accounts receivable related to these customers accounted for 82 % of total accounts receivable, net of allowances on the consolidated balance sheets. Typically, a significant concentration of components and the products sold are manufactured and obtained from single or limited- source suppliers. The loss of any single or limited- source supplier, the failure of any of these suppliers to perform as expected, or the disruption in the supply chain of components from these suppliers could subject the Company to risks and uncertainties including, but not limited to, increased cost of sales, possible loss of revenues, or significant delays in product development or product deliveries, any of which could adversely affect the Company's financial condition and operating results. Deferred tax assets and liabilities are recorded for differences between the financial statement and tax bases of the assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is recorded for the amount of income tax payable for the period increased or decreased by the change in deferred tax assets and liabilities during the period. Research and Development Research and development expense consists of labor and subcontractor costs for internal research and product development activities, direct material to support development programs, laboratory operations, outsourced development and processing work, and other operating expenses. Research and development resources are assigned based on the business opportunity of the available projects, the skill mix of the resources available and the contractual commitments have been made to customers. Research and development costs are expensed as incurred. It is highly likely that a substantial level of continuing research and development expense will be required for the Company to further develop its technology. The Company issues share- based compensation to employees in the form of restricted stock units (RSUs), performance stock units (PSUs), and stock options. Share- based awards are accounted for by recognizing the fair value of share- based compensation expense on a straight- line basis over the service period of the award, net of estimated forfeitures. The fair value of RSUs and PSUs is determined by the closing price of common stock on the date of grant. The fair value of stock options is estimated on the grant date using the Black- Scholes option pricing model. Changes in estimated inputs or using other option valuation methods may result in materially different option values and share- based compensation expense. Recently Adopted Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (" FASB ") issued Accounting Standards Update (" ASU ") 2023- 07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this update expand annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. All disclosure requirements under this standard will also be required for public entities with a single reportable segment. The Company adopted ASU 2023- 07 during the year ended December 31, 2024. Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023- 09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update require disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU 2023- 09 is effective for the Company for annual periods beginning January 1, 2025, with early adoption permitted. The ASU is expected to result in incremental disclosures to the Company's financial statements. In March 2024, the FASB issued ASU No. 2024- 01, Compensation: Stock Compensation (Topic 718). The amendments in this ASU clarify existing guidance related to profits interest and similar awards. ASU 2024- 01 is effective for annual and interim periods for the Company beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the impact this ASU may have on its financial statements and related disclosures. In November 2024, the FASB issued ASU No. 2024- 03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220- 40). The amendments in this ASU require additional disclosure of specified information about certain costs and expenses in the notes to the financial statements. ASU 2024- 03 is effective for annual periods for the Company beginning January 1, 2027, with early adoption permitted. The Company is currently evaluating the impact this ASU may have on its financial statement disclosures. In November 2024, the FASB issued ASU No. 2024- 04, Debt — Debt with Conversion and Other Options (Subtopic 470- 20). The amendments in this ASU clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The amendments in this Update are effective for all entities for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities that have adopted the amendments in Update 2020- 06. The ASU is not expected to have a material impact on the Company's financial statements or disclosures. 3. NET LOSS PER SHARE Basic net loss per share is calculated using the weighted- average number of common shares outstanding during the period. Diluted net loss per share is calculated using the weighted- average number of common shares outstanding and the dilutive effect of all potentially dilutive securities, including common stock equivalents and convertible securities. As the effect of dilutive securities outstanding during the period is anti- dilutive, diluted net loss per share is equal to basic net loss per share. The components of basic and diluted net loss per share are as follows (in thousands, except loss per share data):

	2024	2023	2022
Numerator: Net loss available for common shareholders- basic and diluted	\$ (96, 915)	\$ (82, 842)	\$ (53, 091)
Denominator: Weighted- average common shares outstanding- basic and diluted	209, 510	182, 802	165, 958
Net loss per share- basic and diluted	\$ (0. 46)	\$ (0. 45)	\$ (0. 32)

For the years ended December 31, 2024, 2023 and 2022, the following securities from net loss per share have been excluded as the effect of including them would have been anti- dilutive: outstanding options exercisable into a total of 0. 7 million, 0. 8 million, and 0. 9

million shares of common stock, respectively; 12.0 million, 10.0 million and 8.9 million nonvested restricted and performance stock units, respectively; and 34.6 million shares of common stock that may be issued through conversion of the derivative liability (see Note 7. Notes Payable and Derivative Liability).

**4. BUSINESS COMBINATION** On January 31, 2023, the Company completed the acquisition of certain net assets of Ibeo, a lidar hardware and software provider based in Hamburg, Germany. The purpose of the acquisition was to acquire certain Ibeo assets, primarily intellectual property and personnel, which enabled the Company to expand their technology and product portfolio and diversify revenue streams. Total consideration related to this transaction was approximately EUR 20.0 million or \$ 21.6 million, consisting of approximately (i) EUR 7.0 million or \$ 7.6 million in cash paid at closing, (ii) EUR 6.6 million or \$ 7.1 million in cash advanced to Ibeo prior to closing, (iii) EUR 3.0 million or \$ 3.3 million released from escrow during the quarter ended March 31, 2024, (iv) EUR 0.6 million or \$ 0.7 million in costs paid on behalf of the seller, and (v) EUR 2.7 million or approximately \$ 3.0 million after calculating the deduction in purchase price agreed between both the parties. The remaining balance of approximately EUR 2.7 million was paid during the three months ended June 30, 2024 and was previously recorded as an accrued liability for Ibeo business combination on the consolidated balance sheet. In addition, the Company incurred \$ 0.6 million of acquisition-related costs associated with the acquisition during the three months ended March 31, 2023, which were included in Sales, marketing, general and administrative expense. The transaction was accounted for as a business combination. The results of operations for the acquisition are included in the consolidated financial statements from the date of acquisition onwards. The following table summarizes the final purchase price allocation to assets acquired and liabilities assumed (in thousands):

**SCHEDULE OF PURCHASE PRICE ALLOCATION TO ASSETS ACQUIRED AND LIABILITIES ASSUMED**

Weighted Average Amount Useful Life (in years)	Total purchase consideration
Inventory	\$ 1,197
Other current assets	703
Operating lease right-of-use assets	234
Property and equipment, net	5,330
Intangible assets: Acquired technology	(1) 17,987
Order backlog	261
Contract liabilities	(1,178)
Operating lease liabilities	(234)
Deferred tax liabilities	(785)
Total identifiable net assets	\$ 23,280
Bargain purchase gain	(2) (1,669)

(1) During the year ended December 31, 2024, the Company recognized a \$ 4.2 million impairment charge on certain identified intangible assets acquired in this business combination. See Note 8. Financial Statement Components. (2) The bargain purchase gain represents the excess of the fair value of the underlying net assets acquired and liabilities assumed over the purchase consideration and is included in bargain purchase gain, net of tax in the consolidated statements of operations. The bargain purchase gain was attributable to the negotiation process with Ibeo during its insolvency proceedings resulting in cash consideration paid being less than the fair value of the net assets acquired. The estimated fair value of acquired technology was calculated through the income approach using the multi-period excess earnings and relief from royalty methodologies. The estimated fair value of the order backlog was calculated through the income approach using the multi-period excess earnings methodology. Revenue and net income from the acquisition included in the consolidated statement of operations from the acquisition date through December 31, 2023 is \$ 2.3 million and \$ 3.9 million, respectively.

**5. REVENUE RECOGNITION** Disaggregation of Revenue The following table provides information about disaggregated revenue by timing of revenue recognition (in thousands):

**SCHEDULE OF DISAGGREGATION OF REVENUE**

Revenue	Revenue	Revenue	Total	Year Ended December 31, 2024	License and Product	Royalty	Contract	Revenue
Revenue	Revenue	Total	Timing of revenue recognition: Products transferred at a point in time	\$ 4,117	\$ 475	\$ 104	\$ 4,696	Revenue
Revenue	Revenue	Total	Timing of revenue recognition: Products transferred over time	\$ 4,117	\$ 475	\$ 104	\$ 4,696	Revenue
Revenue	Revenue	Total	Timing of revenue recognition: Products transferred at a point in time	\$ 1,019	\$ 4,888	\$ 1,106	\$ 7,013	Revenue
Revenue	Revenue	Total	Timing of revenue recognition: Products transferred over time	\$ 246	\$ 246	\$ 1,019	\$ 4,888	\$ 1,352
Revenue	Revenue	Total	Year Ended December 31, 2022	License and Product	Royalty	Contract	Revenue	Revenue
Revenue	Revenue	Total	Timing of revenue recognition: Products transferred at a point in time	\$ -	\$ 664	\$ -	\$ 664	Revenue
Revenue	Revenue	Total	Timing of revenue recognition: Products transferred over time	\$ -	\$ 664	\$ -	\$ 664	Revenue

The following table provides information about revenue and long-lived assets, which is comprised of property and equipment, net, and operating lease right-of-use assets, by geographic area (in thousands):

**SCHEDULE OF INFORMATION ABOUT REVENUE AND LONG-LIVED ASSETS**

December 31, 2024	December 31, 2023	December 31, 2022	Geographic Area	Revenue	Long-Lived Assets	Revenue	Long-Lived Assets	Revenue	Long-Lived Assets
\$ 1,058	\$ 17,583	\$ 4,627	United States	\$ 19,580	\$ 664	\$ 21,409	Germany	3,628	6,224
3,210	2,138	3,210	Other foreign countries	10,494	---	---	Total	\$ 4,696	\$ 23,807
\$ 7,259	\$ 22,790	\$ 664	Total	\$ 21,409	Contract Balances Under Topic 606, the Company's rights to consideration are presented separately depending on whether those rights are conditional or unconditional. Unconditional rights to consideration are included within accounts receivable, net of allowances in the consolidated balance sheets. Significant changes in the contract assets and the contract liabilities balances during the period are as follows (in thousands, except percentages):				

**SCHEDULE OF CONTRACT WITH CUSTOMER, CONTRACT ASSET, CONTRACT LIABILITY, AND RECEIVABLE**

December 31, 2024	December 31, 2023	\$ Change	% Change
\$ 926	\$ 949	\$ (23)	(2.4)
(308)	(300)	(8)	(2.7)
\$ 618	\$ 649	\$ (31)	(4.8)

**Contract Acquisition Costs** The Company is required to capitalize certain contract acquisition costs consisting primarily of commissions paid when contracts are signed. As the Company currently does not pay any commissions upon the signing of a contract, no commission cost has been incurred as of December 31, 2024.

**Transaction Price Allocated to the Remaining Performance Obligations** The remaining balance of the contract liabilities was approximately \$ 0.3 million as of December 31, 2024. The Company expects to recognize 100% of this revenue over the next 12 months.

**6. INVESTMENT SECURITIES, AVAILABLE-FOR-SALE AND FAIR VALUE MEASUREMENTS** Investment securities, available-for-sale is comprised of corporate and government debt securities. The principal markets for the debt securities are dealer markets which have a high level of price

transparency. The market participants for debt securities are typically large money center banks and regional banks, brokers, dealers, pension funds, and other entities with debt investment portfolios. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three level fair value inputs hierarchy and requires an entity to maximize the use of observable valuation inputs and minimize the use of unobservable inputs. The Company uses market data, assumptions, and risks that market participants would use in measuring the fair value of the asset or liability, including the risks inherent in the inputs and the valuation techniques. The hierarchy is summarized below. Level 1- Quoted prices in active markets for identical assets and liabilities at the measurement date that the reporting entity has the ability to access. Level 2- Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3- Unobservable inputs for which there is little or no market data, which requires us to develop our own assumptions, which are significant to the measurement of the fair values. The valuation inputs hierarchy classification for assets measured at fair value on a recurring basis are summarized below as of December 31, 2024 and 2023 (in thousands). These tables do not include cash held in money market savings accounts.

**SCHEDULE OF FAIR VALUE HIERARCHY ASSETS AND LIABILITIES**

	As of December 31, 2024	Level 1	Level 2	Level 3	Total
Investment securities, available for sale: Corporate debt securities	\$ 14,001	\$ 14,001			\$ 14,001
U. S. Treasury securities	6,215	6,215			6,215
As of December 31, 2023					
Investment securities, available for sale: Corporate debt securities	\$ 8,471	\$ 8,471			\$ 8,471
U. S. Treasury securities	20,140	20,140			20,140
Short-term investments	28,611				28,611

Short-term investments are summarized below as of December 31, 2024 and 2023 (in thousands).

**SCHEDULE OF UNREALIZED GAIN OR LOSS ON SHORT-TERM INVESTMENTS**

	Investment Cost / Gross Gains	Gross Securities	Amortized	Unrealized	Unrealized Available-Cost
As of December 31, 2024					
Investment securities, available for sale: Corporate debt securities	\$ 13,984	\$ 18	\$ 14,002		
U. S. Treasury securities	6,206	8	6,214	\$ 20,190	\$ 26
As of December 31, 2023					
Investment securities, available for sale: Corporate debt securities	\$ 8,466	\$ 6	(\$ 1)	\$ 8,471	
U. S. Treasury securities	20,119	21	20,140	\$ 28,585	\$ 27
	(\$ 1)			\$ 28,611	

The maturities of the investment securities, available-for-sale as of December 31, 2024 and 2023 are shown below (in thousands):

**SCHEDULE OF MATURITY DATE OF AVAILABLE-FOR-SALE SECURITIES**

	Gross	Gross Amortized	Unrealized	Unrealized Estimated	Cost Gains	Losses	Fair Value
As of December 31, 2024							
Maturity date Less than one year	\$ 20,190	\$ 26	(\$ 20,216)				
As of December 31, 2023							
Maturity date Less than one year	\$ 28,585	\$ 27	(\$ 1)	\$ 28,611			

The following table summarizes investments that have been in a continuous unrealized loss position for less than 12 months and those that have been in a continuous unrealized loss position for more than 12 months as of December 31, 2024 and 2023 (in thousands):

**SCHEDULE OF UNREALIZED LOSS ON INVESTMENTS SECURITIES**

	Less than Twelve Months	Twelve Months or Greater	Total	Gross	Gross
As of December 31, 2024					
Corporate debt securities	\$ 1,245	\$ -	\$ 1,245	\$ -	\$ -
U. S. Treasury securities	1,486	1,486	2,974	(\$ 2)	(\$ 1)

**7. NOTES PAYABLE AND DERIVATIVE LIABILITY**

**Background** On October 14, 2024, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") for the purchase of senior secured convertible notes (the "Note") with an institutional investor (the "Holder"). The principal amount for the initial note is \$ 45.0 million (the "Initial Principal Amount"), with an option for the Company to issue additional principal in the amount of \$ 30.0 million (the "Additional Principal Amount" and, together with the Initial Principal Amount, the "Principal Amount") of convertible notes to the Holder, subject to certain limitation. The Note will rank senior to all outstanding and future indebtedness of the Company. Beginning on January 1, 2025, the Holder may elect to require the Company to partially repay the Notes up to \$ 1.8 million monthly prior to April 1, 2025, and up to \$ 3.5 million monthly on and after April 1, 2025, plus a 10 % premium. In lieu of electing a partial repayment in each of the stated months, the Holder has the right to convert the Note to shares of the Company's common stock at a conversion price of \$ 0.7462 prior to June 1, 2025 and \$ 1.5960 on or after June 1, 2025, subject to certain conditions. Additionally, the Company has the option to require the Holder to convert the entire Note to shares of common stock if the share price exceeds \$ 2.3940 on each of 20 consecutive VWAP Trading Days, subject to certain other equity conditions. If not fully repaid or converted, the end of term maturity balance is the outstanding principal balance of the Note multiplied by 110 % and matures on October 1, 2026. The Note bears zero coupon. Pursuant to terms of the Note, the Company will maintain minimum liquidity of \$ 30.0 million for the duration of the Note term, subject to decreases beginning on May 1, 2025. On October 23, 2024, the Purchase Agreement closed and the Note was issued for net proceeds of approximately \$ 38.1 million, inclusive of all discounts, fees, and expenses related to the transaction. On December 30, 2024, pursuant to the terms of the Note, the Holder elected to convert \$ 1.8 million of outstanding principal into 2,345,068 shares of the Company's common stock. See Note 16. Subsequent Events for details of additional conversions subsequent to the date of these financial statements. The Note is a convertible debt instrument with multiple redemption, conversion, and put features. Certain features qualify as embedded derivatives requiring bifurcation. Therefore, the bifurcated features are accounted for separately as a compound embedded derivative in accordance ASC 815, "Derivatives and Hedging" and are included in the derivative liability on the consolidated balance sheets. The host contract, which represents the Note excluding the derivative liability, is accounted for as non-convertible debt under ASC 470, "Debt" and is included in notes payable, current and notes payable, net of current portion on the consolidated balance sheets. The host contract is

recorded at the total amount repayable at maturity of \$ 49. 5 million, comprised of \$ 45. 0 million principal plus a \$ 4. 5 million 10 % repayment premium, less any conversions of outstanding principal, net of debt discount and issuance costs. The debt discount is equal to the amount repayable at maturity, net of cash proceeds received at issuance and the initial fair value of the bifurcated derivative liability. Debt issuance costs are comprised of qualifying expenses resulting directly from the transaction. During the year ended December 31, 2024, conversions reduced the amount repayable at maturity to \$ 47. 6 million. Supplemental balance sheet information is as follows: SCHEDULE OF SUPPLEMENT BALANCE SHEET (in thousands) 2024 2023 Year Ended December 31, (in thousands) 2024 2023 Amount repayable at maturity \$ 47, 575 \$- Unamortized debt discount (12, 021)- Unamortized issuance costs (2, 552)- Net carrying amount 33, 002- Interest expense related to the amortization of the debt discount and issuance costs was \$ 4. 4 million for the year ended December 31, 2024, and \$ 0. 0 million for the year ended December 31, 2023. The monthly effective interest rate implicit in the Note as of December 31, 2024 under the interest method was 5. 1 %. Maturities of partial repayments, if elected by the Holder, are as follows: SCHEDULE OF MATURITIES LONG TERM DEBT (in thousands) Years Ended December 31, Maturities 2025 \$ 38, 500 2026 9, 075 Total partial repayments \$ 47, 575 Subsequent to December 31, 2024, the partial repayment amounts and maturity schedule were modified (see Note 16. Subsequent Events). The derivative liability was initially recorded at its fair value of \$ 7. 5 million as of the issuance date of October 23, 2024. The derivative liability is subsequently remeasured and reported at fair value each reporting period, with the changes in fair value recorded as an unrealized gain or loss and recognized in earnings. The fair value of derivatives not designated as hedging instruments are as follows: SCHEDULE OF DERIVATIVES INSTRUMENTS (in thousands) 2024 2023 Year Ended December 31, (in thousands) 2024 2023 Derivative liability \$ 14, 581 \$- Total \$ 14, 581 \$- Unrealized gains and losses associated with derivatives not designated as hedging instruments are as follows: SCHEDULE OF UNREALIZED GAIN AND LOSS INSTRUMENTS (in thousands) 2024 2023 2022 Year Ended December 31, (in thousands) 2024 2023 2022 Unrealized loss on derivative liability \$ (8, 866) \$- Total \$ (8, 866) \$- Fair Value Measurements The fair value of the derivative liability is determined utilizing a “ with and without ” method, in which the fair value is calculated as the difference in the fair value of the entire hybrid instrument and the fair value of the instrument excluding the bifurcated derivative features. The fair value of the hybrid instrument is estimated using a binomial lattice model, which projects future movements of the underlying instrument over the remaining term. The model then calculates the fair value of the instrument by discounting projected cash flows based on the optimal action at each point in time. Optimal actions for both the Company and the Holder are determined by the projected stock price at a point in time, in addition to the probabilities of the occurrence of certain events. At initial measurement on October 23, 2024, a Monte Carlo simulation was further incorporated in order to simulate the Company’s share price as of the registration date, which occurred on November 21, 2024. The fair value of the host contract excluding embedded derivative features is estimated using a debt discounted cash flow model, which assumes that the contract is a debt instrument with only the option to redeem partial principal payments prior to maturity. Projected cash flows are based on the assumption that the Holder will fully exercise early redemption options, based on the estimated internal rate of return for the Holder resulting from early redemption as compared to redemption at maturity. The debt discount rate is estimated based on the rate of similar non-convertible debt instruments reflecting the Company’s credit risk. The valuation inputs hierarchy classification for liabilities measured at fair value on a recurring basis are summarized below as of December 31, 2024 and 2023 (in thousands). See Note 6. Investment Securities, Available- For- Sale and Fair Value Measurements, for discussion of the fair value level hierarchy. SCHEDULE OF HIERARCHY LIABILITIES FAIR VALUEAs of December 31, 2024 Level 1 Level 2 Level 3 Derivative liability \$- \$- \$ 14, 581 Total \$- \$- \$ 14, 581 The table below lists the inputs and assumptions for the Company’s initial valuation as of October 23, 2024 and re- valuation of the derivative liability as of December 31, 2024: SCHEDULE OF REVALUATION DERIVATIVE LIABILITY December 31, October 23, 2024 2024 Expected term (years) 1. 75 1. 94 Risk- free interest rate 4. 18 % 4. 04 % Dividend yield 0 % 0 % Volatility 78. 02 % 73. 00 % Discount rate 50. 0 % 50. 0 % 8. FINANCIAL STATEMENT COMPONENTS During the year ended December 31, 2024, Restricted cash, current decreased largely due to a \$ 3. 3 million release of escrow in connection with the Asset Purchase Agreement with Ibeo. In addition, Restricted cash, net of current portion increased by approximately \$ 1. 0 million related to cash that is held as collateral for a Hamburg, Germany lease. Inventory consists of the following (in thousands): SCHEDULE OF COMPONENTS OF INVENTORY 2024 2023 December 31, 2024 2023 Raw materials \$ 1, 616 \$ 1, 574 Work in process- 305 Finished goods 678 1, 995 Total inventory \$ 2, 294 \$ 3, 874 Inventory is computed using the first- in, first- out (FIFO) method and is stated at the lower of cost and net realizable value. Management periodically assesses the need to account for obsolescence of inventory and adjusts the carrying value of inventory to its net realizable value when required. During the year ended December 31, 2024, the Company recorded a \$ 2. 0 million reduction to inventory due to obsolescence. Property and equipment consists of the following (in thousands): SCHEDULE OF COMPONENTS OF PROPERTY, PLANT AND EQUIPMENT 2024 2023 December 31, 2024 2023 Production equipment \$ 6, 140 \$ 6, 140 Leasehold improvements 3, 957 3, 843 Computer hardware and software / lab equipment 12, 211 12, 149 Office furniture and equipment 4, 973 5, 367 Property and equipment, gross 27, 281 27, 499 Less: Accumulated depreciation (20, 220) (18, 467) Property and equipment, net \$ 7, 061 \$ 9, 032 Depreciation expense was \$ 2. 1 million, \$ 3. 1 million, and \$ 0. 7 million for the years ended December 31, 2024, 2023 and 2022 respectively. The components of intangible assets are as follows: SUMMARY OF COMPONENTS OF INTANGIBLE ASSETSAs of December 31, 2024 Gross Net Weighted Average Remaining Carrying Accumulated Impairment Carrying Period (in thousands) Amount Amortization Expense Amount (Years) Acquired technology \$ 20, 172 \$ 5, 019 \$ 4, 181 \$ 10, 972 13 Backlog----- \$ 20, 172 \$ 5, 019 \$ 4, 181 \$ 10, 972 As of December 31, 2023 Gross Net Weighted Average Remaining Carrying Accumulated Impairment Carrying Period (in thousands) Amount Amortization Expense Amount (Years)

Acquired technology \$ 20, 172 \$ 2, 940 \$- \$ 17, 232 12 Backlog 26 23- 3- \$ 20, 198 \$ 2, 963 \$- \$ 17, 235 Amortization expense was \$ 2. 1 million, \$ 2. 1 million, and \$ 0. 0 million for the years ended December 31, 2024, 2023 and 2022, respectively. During the quarter ended June 30, 2024, management identified various factors related to the 2024 restructuring events (see Note 14. Restructuring Charges) that collectively indicated that it is more- likely- than- not that the fair value of the Company' s Reference software intangible asset was less than its carrying amount as of June 30, 2024. As of June 30, 2024, prior to impairment, the fair value was \$ 4. 5 million. As a result, the Company performed an impairment assessment for intangibles in accordance with ASC 360, Property, Plant and Equipment. The June 30, 2024 impairment test indicated a decline in the carrying amount of the Reference software intangible asset and a reduction in the asset' s useful life, resulting in a non- cash impairment charge of \$ 3. 0 million. As part of the Company' s annual impairment assessment, management identified further factors that indicated the Company' s Reference software intangible asset is more- likely- than- not fully impaired. As of December 31, 2024, prior to impairment, the fair value was \$ 1. 2 million. An additional non- cash impairment charge of \$ 1. 2 million was recorded, resulting in a combined non- cash impairment charge of \$ 4. 2 million that is included in impairment loss on intangible assets on the consolidated statement of operations. As of December 31, 2024, the fair value of Reference software is fully written off. The following table outlines estimated future amortization expense related to intangible assets held as of December 31, 2024 (in thousands):

SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE RELATED TO INTANGIBLE ASSETS	
Research and Development	Cost of Development
2025	\$ 869
2026	\$ 54
2027	\$ 923
2028	\$ 869
2029	\$ 27
2030	\$ 896
2031	\$ 829
2032	\$ 1
2033	\$ 830
2034	\$ 825
2035	\$ 825
2036	\$ 825
2037	\$ 825
2038	\$ 825
2039	\$ 825
2040	\$ 825
Thereafter	\$ 6, 673
Total	\$ 10, 890

Accrued Liabilities Accrued liabilities consists of the following (in thousands):

SCHEDULE OF ACCRUED LIABILITIES	
2024	2023
December 31, 2024	December 31, 2023
Bonuses	\$ 571
Payroll and payroll taxes	\$ 1, 359
Income taxes payable	20 2, 111
Accrued professional fees	140 236
Liabilities to suppliers	381 885
Other	303 345
Total accrued liabilities	\$ 2, 542
	\$ 8, 640

In addition, as of December 31, 2023, the accrued liability for Ibeo business combination on the consolidated balance sheet in the amount of \$ 6. 3 million included \$ 3. 3 million that was withheld from the Purchase Price and held in escrow for a maximum period of 13 months post- Closing as partial security for potential claims arising out of or in connection with the Asset Purchase Agreement and a \$ 3. 0 million holdback. Both were settled during the year ended December 31, 2024.

9. SHARE- BASED COMPENSATION The Company issues share- based compensation to employees in the form of restricted stock units (RSUs), performance stock units (PSUs), and stock options. The following table summarizes the amount of share- based compensation expense by line item on the consolidated statements of operations:

SCHEDULE OF SHARE- BASED COMPENSATION EXPENSE	
2024	2023
Year Ended December 31, 2024	Year Ended December 31, 2023
Research and development expense	\$ 3, 973
Sales, marketing, general and administrative expense	\$ 6, 531
Total Share- based compensation expense	\$ 6, 933
	\$ 11, 535
	\$ 16, 141
	\$ 15, 461

Options Activity and Positions The following table summarizes shares, weighted- average exercise price, weighted- average remaining contractual term, and aggregate intrinsic value of options outstanding and options exercisable as of December 31, 2024 (in thousands, except per share data):

SCHEDULE OF OPTIONS ACTIVITY AND POSITIONS					
Weighted- average	Aggregate remaining intrinsic	Weighted- average contractual	Options	Shares	exercise price
term (in years)	(thousands)	value	Outstanding	exercise price	term (in years)
Outstanding as of December 31, 2021	1, 533	\$ 1. 37	5. 6	\$ 5, 645	Granted-- Exercised (525)
Forfeited or expired (63)	3. 00	Outstanding as of December 31, 2022	945	\$ 1. 26	5. 7
Outstanding as of December 31, 2022	752	\$ 1. 35	4. 6	\$ 1, 083	Granted-- Exercised (84)
Forfeited or expired (2)	0. 28	Outstanding as of December 31, 2023	752	\$ 1. 35	4. 6
Outstanding as of December 31, 2023	666	\$ 1. 43	3. 5	\$ 185	Vested and expected to vest as of December 31, 2024
Forfeited or expired (2)	1. 18	Outstanding as of December 31, 2024	666	\$ 1. 43	3. 5
Outstanding as of December 31, 2024	666	\$ 1. 43	3. 5	\$ 185	Exercisable as of December 31, 2024
					\$ 1. 43
					3. 5

As of December 31, 2024, there is no unrecognized share- based employee compensation related to stock options. Restricted Stock Activity and Positions The following table summarizes activity and positions with respect to RSUs and PSUs for the years ended December 31, 2024, 2023 and 2022 (in thousands, except per share data):

SCHEDULE OF ACTIVITY AND POSITIONS WITH RESPECT TO RSUs AND PSUs	
Weighted- average	Shares price
Unvested as of December 31,	Unvested as of December 31,
2021	2, 625
Granted	\$ 13. 05
9, 180	2. 46
Vested (1, 391)	9. 16
Forfeited (1, 548)	6. 42
Unvested as of December 31, 2022	8, 866
Granted	3. 85
3, 491	3. 89
Vested (1, 872)	6. 98
Forfeited (502)	7. 47
Unvested as of December 31, 2023	9, 983
Granted	3. 09
9, 234	1. 26
Vested (5, 437)	3. 63
Forfeited (1, 767)	2. 65
Unvested as of December 31, 2024	12, 013
	\$ 1. 51

During the year ended December 31, 2024, the Company granted 5, 384, 000 shares to non- executive employees for annual and short- term incentive awards. Additionally, the Company granted 80, 000 shares to non- executive employees for new hire grants. These shares are valued based on the closing price of common stock on the dates of grant and vest immediately or over three or four years. During the year ended December 31, 2024, the Company granted 3, 771, 000 shares to executive employees and directors for annual, short- term incentive, and long- term incentive awards. These shares are valued based on the closing price of common stock on the dates of grant and vest immediately, over one year, or over three years. As of December 31, 2024, unrecognized share- based compensation related to RSUs was \$ 6. 8 million, which will be expensed over the next 2. 0 years. Unrecognized share- based compensation related to executive PSUs was \$ 2. 5 million, which will be expensed over the next 1. 0 year. Unrecognized share- based compensation related to the non- executive PSUs was \$ 0. 3 million, which will be expensed over the next 0. 5 years.

10. LEASES The Company leases office space and certain equipment under operating and finance leases. All leases have remaining lease terms of one to eight years. Office lease agreements include both lease and non- lease components, which are accounted for separately. Finance leases contain options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless the Company is reasonably certain to exercise the purchase option. In September 2021, the Company entered into a lease agreement for product testing and lab space in Redmond, Washington which commenced in November 2021. In addition to base rent, the Company pays additional rent comprised

of a proportionate share of any operating expenses, real estate taxes, and management fees. The lease, which expires in July 2032, includes an option to extend the term for one ten- year renewal period. In September 2021, the Company entered into a lease agreement for office space in Redmond, Washington which commenced in December 2022. In addition to base rent, the Company will pay additional rent comprised of a proportionate share of any operating expenses, real estate taxes, and management fees. During the quarter ended June 30, 2023, a payment of \$ 3. 0 million was received as an incentive to terminate the Company’ s previous lease. The gain is recorded as other income in the consolidated statements of operations. The lease, which expires in December 2032, contains an option to extend the term for one ten- year renewal period. Subsequent to the date of these financial statements, on February 13, 2025, the Company signed a Letter of Intent (“ LOI ”) with a third party to sublease a portion of this office space. The sublease, which, if executed, would commence on or around April 1, 2025, has an expected term of 57 months and expected monthly rent of \$ 0. 1 million. In April 2022, the Company entered into a lease agreement for product testing for engineering and development activities in Nuremberg, Germany which commenced in May 2022. In June 2024, the Company abandoned the space prior to its expiration of November 2027. During the year ended December 31, 2024, impairment expense of \$ 0. 2 million was incurred and is recorded within sales, marketing, general and administrative expense on the consolidated statements of operations. In September 2022, the Company entered into a lease agreement for office space in Nuremberg, Germany which commenced in November 2022. In June 2024, the Company entered into an early termination agreement to decrease the expiration from April 2027 to April 2025, resulting in an insignificant early termination fee. During the year ended December 31, 2024, impairment expense of \$ 0. 1 million was incurred and is recorded within sales, marketing, general and administrative expense on the consolidated statements of operations. Additionally, in connection with the January 2023 acquisition of assets from Ibeo, the Company assumed three leases in Hamburg, Germany. Each lease was abandoned or expired in 2024, resulting in impairment expense of \$ 0. 1 million during the year ended December 31, 2024. In December 2023, the Company entered into a lease agreement for office space in Hamburg, Germany which commenced in November 2024. The lease, which expires in October 2029, includes an option to extend the term for two three- year renewal periods. The components of lease expense are as follows:

SCHEDULE OF COMPONENTS OF LEASE EXPENSE (in thousands)			
	2024	2023	2022
Operating lease expense	\$ 2, 701	\$ 2, 625	\$ 1, 501
Finance lease expense: Amortization of leased assets-	21	26	
Interest on lease liabilities--	2		
Total finance lease expense-	21	28	
Total lease expense	\$ 2, 701	\$ 2, 646	\$ 1, 529

Supplemental cash flow information related to leases is as follows: SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (in thousands)

	2024	2023	2022
Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases	\$ 2, 491	\$ 2, 500	\$ 1, 280
Operating cash flows from finance leases--	2		
Financing cash flows from finance leases-	21	26	

Supplemental balance sheet information related to leases is as follows: SCHEDULE OF BALANCE SHEET INFORMATION RELATED TO LEASES (in thousands)

	2024	2023
Operating leases Operating lease right- of- use assets	\$ 16, 746	\$ 13, 758
Current portion of operating lease liabilities	2, 682	2, 323
Operating lease liabilities, net of current portion	15, 954	12, 714
Total operating lease liabilities	\$ 18, 636	\$ 15, 037
Finance leases Property and equipment, at cost	\$ 112	\$ 112
Accumulated depreciation (112) (97)		
Property and equipment, net \$-	\$ 15	\$ 15
Weighted Average Remaining Lease Term Operating leases	6. 8 years	8. 4 years
Weighted Average Discount Rate Operating leases	4. 9 %	4. 6 %

As of December 31, 2024, maturities of lease liabilities are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES (in thousands)

Operating Years Ended December 31,	2025	2026	2027	2028	2029	Thereafter	Total minimum lease payments
	2, 974	3, 351	3, 316	3, 279	3, 115	5, 716	21, 751
Less: amount representing interest (3, 115)							18, 636

Present value of capital lease liabilities \$ 18, 636 11.

COMMITMENTS AND CONTINGENCIES Purchase Commitments During the quarter ended September 30, 2023, the Company entered into a \$ 9. 3 million purchase commitment with a contract manufacturing partner for the production of MOVIA sensor inventory to support direct sales to both automotive and non- automotive customers. During the quarter ended December 31, 2024, the Company entered into an additional purchase commitment with the existing contract manufacturing partner of \$ 1. 8 million. Remaining future minimum payments of approximately \$ 6. 3 million are expected to be made by the Company through 2025 and 2026. Litigation The Company is subject to various claims and pending or threatened lawsuits in the normal course of business. The Company is not currently party to any legal proceedings that management believes are reasonably possible to have a material adverse effect on financial position, results of operations, or cash flows.

12. COMMON STOCK In March 2024, the Company entered into a \$ 150 million ATM equity offering agreement with Deutsche Bank Securities, Inc., Mizuho Securities USA LLC, and Craig- Hallum Capital Group LLC (collectively, the “ Agents ”). Under the agreement, the Company is able, with discretion, to offer and sell shares of common stock having an aggregate value of up to \$ 150. 0 million through or directly to the Agents. As of December 31, 2024, the sale of 23. 3 million shares for net proceeds of \$ 34. 7 million had been completed. As of December 31, 2024, approximately \$ 113. 6 million is available under this sales agreement, subject to authorized shares available for sale. In June 2023, the Company entered into a \$ 45. 0 million ATM equity offering agreement with Craig- Hallum. Under the agreement, the Company was able, with discretion, to offer and sell shares of common stock having an aggregate value of up to \$ 45. 0 million through Craig- Hallum. As of June 30, 2023, the Company had completed sales under such sales agreement, having sold 10. 9 million shares for net proceeds of \$ 43. 9 million. No further shares are available for sales under this agreement. In June 2021, the Company entered into a \$ 140. 0 million ATM equity offering agreement with Craig- Hallum. Under the agreement, the Company was able, with discretion, to offer and sell shares of common stock having an aggregate value of up to \$ 140. 0 million through Craig- Hallum. As of December 31, 2022, the Company had issued 8. 3 million shares of common stock for net proceeds of \$ 81. 8 million under the

agreement. During the quarter ended March 31, 2023, the Company issued 5.0 million shares of common stock for net proceeds of \$ 12.5 million under the agreement. The sales agreement was terminated in June 2023.

**13. INCOME TAXES** Components of net loss before income taxes are as follows (in thousands):

SCHEDULE OF COMPONENTS OF NET LOSS BEFORE INCOME TAXES	Year Ended December 31, 2024	2023	2022
United States	\$ (97,893)	\$ (86,730)	\$ (53,091)
Foreign	1,485	5,034	-
Total	\$ (96,408)	\$ (81,696)	\$ (53,091)

Components of income tax expense (benefit) are as follows (in thousands):

SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE (BENEFIT)	Year Ended December 31, 2024	2023	2022
Current Federal	\$-	\$-	\$-
State	581	2,061	-
International	2,061	-	-
Total Current Tax Expense	581	2,061	-
Deferred Federal	-	-	-
State	(74)	(915)	-
International	(74)	(915)	-
Total Deferred Tax Expense	(74)	(915)	-
Total Tax Expense	\$ 507	\$ 1,146	\$-

The percentage difference between the effective tax rate of the provision (benefit) for income taxes and the Federal statutory rate is as follows:

SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION	2024	2023	2022
Statutory rate	21.0 %	21.0 %	21.0 %
Permanent Items and adjustments	0.0 %	0.1 %	0.0 %
Compensation related	0.0 %	(0.4) %	(0.5) %
Share-based compensation	(2.4) %	(1.7) %	(2.2) %
Net operating loss expiration	(6.2) %	(6.3) %	(9.0) %
Tax credits	1.0 %	1.0 %	1.5 %
Change in valuation allowance	(11.0) %	(15.0) %	(10.8) %
Bargain Purchase gain	0.0 %	0.9 %	0.0 %
Notes payable related	(2.7) %	0.0 %	0.0 %
Other	(0.2) %	(1.0) %	0.0 %
Total	(0.5) %	(1.4) %	0.0 %

Components of deferred tax assets are as follows (in thousands):

SCHEDULE OF DEFERRED TAX ASSETS	December 31, 2024	2023
Deferred tax assets	\$ 430	\$ 632
Reserves	104	575
Net operating loss carryforwards	97	254
R & D credit carryforwards	11	10
Depreciation / amortization deferred	29	618
Operating lease liabilities	26	079
Other	5	099
Total deferred tax assets	157	249
Deferred tax liabilities:		
Operating lease right-of-use assets	(4)	(106)
Total deferred tax liabilities	(4)	(106)
Net valuation allowances	(152)	(935)
Deferred tax assets	\$ 208	\$ 142

As of December 31, 2024, a valuation allowance of \$ 152.9 million was maintained for deferred tax assets which have been deemed not more likely than not to be realized. As of December 31, 2024, the Company has net operating loss carryforwards of approximately \$ 498.0 million for federal income tax reporting purposes. In addition, the Company has research and development tax credits of \$ 11.1 million. During 2024, \$ 28.2 million federal net operating losses and \$ 0.2 million general business credits expired unused. A majority of the net operating loss carryforwards and research and development credits available to offset future taxable income, if any, will expire in varying amounts from 2025 to 2044, if not previously used. Certain net operating losses arise from the deductibility for tax purposes of compensation under nonqualified stock options equal to the difference between the fair value of the stock on the date of exercise and the exercise price of the options. For financial reporting purposes, the tax effect of this deduction, when recognized, is accounted for as an income tax benefit. In certain circumstances, as specified in the Internal Revenue Code, a 50% or more ownership change by certain combinations of shareholders during any three-year period would result in limitations on the ability to use a portion of net operating loss carryforwards. The Company had no unrecognized tax benefits as of December 31, 2024 or 2023. Interest accrued and penalties related to unrecognized tax benefits are recognized in tax expense. During the years ended December 31, 2024, 2023 and 2022, no interest or penalties were recognized. Income tax returns are filed in the U. S. federal jurisdiction, certain U. S. states, and in Germany. Due to the Company's operating loss and credit carryforwards, the U. S. federal statute of limitations remains open for 2005 and onward. Tax years 2022 and forward remain open in Germany.

**14. RESTRUCTURING CHARGES** In 2024, to better align the Company's resources to support business needs, the Company reduced the global workforce by approximately 41%. The Company recognized approximately \$ 6.0 million in restructuring and related reorganization charges during the year ended December 31, 2024, of which \$ 5.4 million is recorded within research and development expense and \$ 0.6 million within sales, marketing, general and administrative expense on the consolidated statements of operations. The charges were predominately related to employee severance and benefit costs. Consistent with the impairment analyses performed during 2024, the workforce reduction and restructuring included, among other things, impacts from the de-emphasis on the Company's MOSAIK software business.

**15. RETIREMENT SAVINGS PLAN** The Company maintains a retirement savings plan which qualifies under Internal Revenue Code Section 401 (k). The plan covers all qualified employees. Contributions to the plan are made at the discretion of the Board of Directors. During the years ended December 31, 2024, 2023 and 2022, contributions of \$ 0.5 million, \$ 0.5 million, and \$ 0.4 million were made to the plan, respectively.

**16. SUBSEQUENT EVENTS** On January 31, 2025, pursuant to terms of the Note (see Note 7, Notes Payable and Derivative Liability), the Holder elected to immediately convert \$ 1.8 million of outstanding principal into 2,345,068 shares of the Company's common stock. On February 3, 2025, the Company entered into a Letter Agreement with the Holder related to the Note. As a result of the Letter Agreement, the Holder agreed to convert a total of \$ 8.8 million of outstanding principal ("remaining Initial Outstanding Principal") into shares of the Company's common stock. First, on February 4, 2025, the Holder converted \$ 2.8 million of outstanding principal into 3,685,106 shares of common stock pursuant to terms of the Note. Second, on February 20, 2025, the Holder converted \$ 2.0 million of outstanding principal into 2,680,077 shares of common stock pursuant to terms of the Note. Last, on February 21, 2025, the Holder converted \$ 4.0 million of outstanding principal into 5,360,154 shares of common stock pursuant to terms of the Note, thereby converting the entirety of the remaining Initial Outstanding Principal. Additionally, as a result of the Letter Agreement, the Holder agreed to defer \$ 11.6 million of principal repayments to 7 monthly payments of \$ 1.7 million beginning on September 1, 2025 and concluding on March 1, 2026. As of the date of these financial statements are available to be issued, maturities of partial repayments as a result of the Letter Agreement are as follows:

SCHEDULE OF MATURITIES PARTIAL REPAYMENTS	(in thousands)	Years Ended December 31,
2025	\$ 22,000	2026
2026	\$ 14,025	Total partial repayments
2025	\$ 36,025	On February 3, 2025, the Company entered into a new Securities Purchase Agreement (the "2025 Purchase Agreement") with the Holder. In exchange for \$ 8.0 million, the

Holder agreed to purchase up to 5,750,225 shares of common stock and warrants to purchase up to 5,750,225 shares of common stock at an exercise price of \$ 1.57 per share. On February 4, 2025, the 2025 Purchase Agreement closed for net proceeds of approximately \$ 7.8 million, inclusive of initial fees and expenses related to the transaction. ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE There have been no changes in or disagreements with accountants on accounting or financial disclosure matters during our fiscal years ended December 31, 2024, 2023 and 2022. ITEM 9A. CONTROLS AND PROCEDURES (a) Evaluation of Disclosure Controls and Procedures. Our Chief Executive Officer (CEO) and the Chief Financial Officer (CFO) evaluated our disclosure controls and procedures (as defined in Rules 13a-15 (e)) under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), prior to the filing of this Form 10-K. Based upon that evaluation, our CEO and CFO concluded that, as of December 31, 2024, our disclosure controls and procedures were effective. (b) Management's Report on Internal Control Over Financial Reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15 (f). Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on its evaluation under the framework in Internal Control — Integrated Framework (2013), our management concluded that our internal control over financial reporting was effective as of December 31, 2024. (c) Limitations on the Effectiveness of Controls. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. (d) Changes in Internal Control Over Financial Reporting. There were no changes in our internal control over financial reporting during the period ended December 31, 2024 which has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. ITEM 9B. OTHER INFORMATION (a) None. (b) During the three months ended December 31, 2024, none of our directors or officers (as defined in Rule 16a-1 (f) under the Securities Exchange Act of 1934, as amended) adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933, as amended). ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS PART III. ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Information regarding executive officers is included in Part I of this Annual Report on Form 10-K in Item 4A. The information required by this Item 10 of Form 10-K and not provided in Item 4A will be included under the caption "Proposal One – Election of Directors" and "Board of Directors & Governance Matters" in our 2025 Proxy Statement and is incorporated herein by reference. Our 2025 Proxy Statement will be filed with the SEC prior to our 2025 Annual Meeting of Shareholders. ITEM 11. EXECUTIVE COMPENSATION The information required by this Item 11 of Form 10-K will be included under the captions "Executive Compensation," "Compensation Committee Interlocks and Insider Participation," and "Director Compensation for 2024" in our 2025 Proxy Statement and are incorporated herein by reference. ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS Information as of December 31, 2024, regarding equity compensation plans approved and not approved by shareholders is summarized in the following table (in thousands, except per share data):

Equity Compensation Plan Information	Number of securities remaining available for	Number of further issuance under securities to be issued upon	Weighted-average exercise price of plans (excluding options, warrants and restricted stock units)
Equity compensation plans approved by shareholders	12,121	Options to purchase common stock	\$ 1.43
Equity compensation plans not approved by shareholders	12,679	Options to purchase common stock	\$ 2.12

The other information required by this Item 12 of Form 10-K will be included under the caption "Information about MicroVision Common Stock" in our 2025 Proxy Statement and is incorporated herein by reference. ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE The information required by this Item 13 of Form 10-K will be included under the captions "Certain Relationships and Related Transactions" and "Board of Directors & Governance Matters" in our 2025 Proxy Statement and are incorporated herein by reference. ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES The information required by this Item 14 of Form 10-K will be included under the caption "Independent Registered Public Accounting Firm" in our 2025 Proxy Statement and is incorporated herein by reference. PART IV. ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES (A) Documents filed as part of this Annual Report on Form 10-K: 1. Consolidated Financial Statements • Report of Independent Registered Public Accounting Firm • Consolidated Balance Sheets as of December 31, 2024 and 2023 • Consolidated Statements of Operations for the years ended December 31, 2024, 2023 and 2022 • Consolidated Statements of Comprehensive Loss for the years ended December 31, 2024, 2023 and 2022 • Consolidated Statements of Shareholders' Equity for the years ended December 31, 2024, 2023 and 2022 • Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022 • Notes to Consolidated Financial Statements 2. Financial Statement Schedules Schedule II Valuation and Qualifying Accounts and Reserves Schedule Additions Year Ended December 31, Balance at beginning of fiscal period Charges to costs and expenses Charges to other accounts Deductions Balance at end of fiscal period 2022 Tax valuation allowance \$ 124,380 \$ 5,745 \$- \$- \$ 130,125 2023 Tax valuation allowance \$ 130,125 \$ 12,252 \$- \$- \$ 142,377 2024 Tax valuation allowance \$ 142,377 \$ 10,558 \$- \$- \$ 152,935 All other schedules are omitted because they are not applicable, or because the information required is included in the consolidated financial statements and notes thereto. 3. Exhibits The following exhibits are

referenced or included in this Annual Report on Form 10- K. Exhibit Number Description 2. 1 Asset Purchase Agreement, dated December 1, 2022, by and between Ibeo Automotive Systems GmbH and MicroVision GmbH (14) 2. 2 Amendment Agreement, dated January 31, 2023, to the Asset Purchase Agreement, dated December 1, 2022, by and between Ibeo Automotive Systems GmbH and MicroVision GmbH (14) 3. 1 Amended and Restated Certificate of Incorporation of MicroVision, Inc., as amended (2) 3. 2 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MicroVision, Inc (4) 3. 3 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MicroVision, Inc. dated June 7, 2018 (6) 3. 4 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MicroVision, Inc. dated October 8, 2020 (8) 3. 5 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MicroVision, Inc. dated May, 18, 2023 (7) 3. 6 Amended and Restated Bylaws of MicroVision, Inc (5) 4. 1 Form of Specimen Stock Certificate for Common Stock (1) 4. 2 Description of Common Stock (9) 4. 3 Form of Senior Secured Convertible Note (19) 10. 1 MicroVision, Inc. Incentive Plan (13) \* 10. 2 Lease Agreement Concerning Office Premises between Victoria Immo Properties I.S. à r.l., dated December 15, 2023 (covering approximately 60, 000 square feet) (20) 10. 3 Key Executive Severance and Change in Control Plan (3) \* 10. 4 Employment Agreement between MicroVision, Inc. and Sumit Sharma dated April 8, 2021 (11) 10. 5 At- the- Market Issuance Sales Agreement, dated August 29, 2023, by and between the Company and Craig- Hallum Capital Group LLC (10) 10. 6 Lease Agreement between Redmond East Office Park LLC and MicroVision, Inc. dated September 24, 2021 (covering approximately 16, 681 square feet) (12) 10. 7 Lease Agreement between Redmond East Office Park LLC and MicroVision, Inc. dated September 24, 2021 (covering approximately 36, 062 square feet) (12) 10. 8 Form of Performance- Based Restricted Stock Unit Agreement (13) \* 10. 9 Form of Restricted Stock Unit Agreement (15) \* 10. 10 At- the- Market Issuance Sales Agreement, dated June 16, 2023, by and between the Company and Craig- Hallum Capital Group LLC (16) 10. 11 2024 Executive Bonus Plan (3) 10. 12 At- the- Market Issuance Sales Agreement, dated March 5, 2024, by and among the Company and various banks (17) 10. 13 2024 CEO Agreement (18) \* 10. 14 Securities Purchase Agreement (19) 19. 1 MicroVision Statement of Policy on Insider Trading and Pre- Clearance Procedures 21. 1 List of Subsidiaries of the Registrant 23. 1 Consent of Independent Registered Public Accounting Firm – Moss Adams LLP 31. 1 Principal Executive Officer Certification pursuant to Rule 13a- 14 (a) / 15d- 14 (a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes- Oxley Act of 2002 31. 2 Principal Financial Officer Certification pursuant to Rule 13a- 14 (a) / 15d- 14 (a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes- Oxley Act of 2002 32. 1 Principal Executive Officer Certification pursuant to Rule 13a- 14 (b) or Rule 15d- 14 (b) and Section 1350, Chapter 63 of Title 18, United States Code (18 U. S. C. 1350), as adopted pursuant to Section 906 of Sarbanes- Oxley Act of 2002 32. 2 Principal Financial Officer Certification pursuant to Rule 13a- 14 (b) or Rule 15d- 14 (b) and Section 1350, Chapter 63 of Title 18, United States Code (18 U. S. C. 1350), as adopted pursuant to Section 906 of Sarbanes- Oxley Act of 2002 97. 1 Policy on Recoupment of Incentive Compensation 101. INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). 101. SCH Inline XBRL Taxonomy Extension Schema 101. CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101. DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101. LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101. PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) (1) Incorporated by reference to the Company’ s Post- Effective Amendment to Form S- 3 Registration Statement, Registration No. 333- 102244. (2) Incorporated by reference to the Company’ s Form 10- Q for the quarterly period ended September 30, 2009. (3) Incorporated by reference to the Company’ s Form 10- Q for the quarterly period ended June 30, 2024. (4) Incorporated by reference to the Company’ s Current Report on Form 8- K filed on February 17, 2012. (5) Incorporated by reference to the Company’ s Current Report on Form 8- K filed on July 14, 2023. (6) Incorporated by reference to the Company’ s Amendment No. 2 to Form S- 1 Registration Statement, Registration No. 333- 222857. (7) Incorporated by reference to the Company’ s Current Report on Form 8- K filed on May 19, 2023. (8) Incorporated by reference to the Company’ s Form 10- Q for the quarterly period ended September 30, 2020. (9) Incorporated by reference to the Company’ s Form 10- K for the year ended December 31, 2020. (10) Incorporated by reference to the Company’ s Current Report on Form 8- K filed on August 29, 2023. (11) Incorporated by reference to the Company’ s Form 10- Q for the quarterly period ended June 30, 2021. (12) Incorporated by reference to the Company’ s Form 10- Q for the quarterly period ended September 30, 2021. (13) Incorporated by reference to the Company’ s Form S- 8 filed on June 8, 2022. (14) Incorporated by reference to the Company’ s Current Report on Form 8- K filed on February 3, 2023. (15) Incorporated by reference to the Company’ s Form 10- K for the year ended December 31, 2022. (16) Incorporated by reference to the Company’ s Current Report on Form 8- K filed on June 16, 2023. (17) Incorporated by reference to the Company’ s Current Report on Form 8- K filed on March 5, 2025. (18) Incorporated by reference to the Company’ s Form 10- Q for the quarterly period ended September 30, 2024. (19) Incorporated by reference to the Company’ s Current Report on Form 8- K filed on October 15, 2024. (20) Incorporated by reference to the Company’ s Form 10- K for the year ended December 31, 2023. \* Management contracts and compensatory plans and arrangements required to be filed as exhibits pursuant to Item 15 (b) of this Annual Report on Form 10- K. ITEM 16. FORM 10- K SUMMARY None. SIGNATURES Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MicroVision, Inc. Date: March 26, 2025 By / s / Sumit Sharma Sumit Sharma Chief Executive Officer and Director POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sumit Sharma and Anubhav Verma, jointly and severally, his or her attorneys-

in- fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10- K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys- in- fact, or his substitute or substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the following capacities on March 26, 2025. Signature Title / s / Sumit Sharma Chief Executive Officer and Director Sumit Sharma (Principal Executive Officer) / s / Anubhav Verma Chief Financial Officer Anubhav Verma (Principal Financial Officer and Principal Accounting Officer) / s / Simon Biddiscombe Director Simon Biddiscombe / s / Robert P. Carlile Director Robert P. Carlile / s / Jeffrey Herbst Director Jeffrey Herbst / s / Peter Schabert Director Peter Schabert / s / Jada Smith Director Jada Smith / s / Mark Spitzer Director Mark Spitzer

**Exhibit 19. 1 MicroVision Statement of Policy on Insider Trading** It is illegal for any person, either personally or on behalf of others, to trade in securities on the basis of material, nonpublic information. It is also illegal to communicate (to “ tip ”) material, nonpublic information to others so that they may trade in securities on the basis of that information. These illegal activities are commonly referred to as “ insider trading. ” In the course of your employment or service with MicroVision and its subsidiaries (the “ Company ”) you may become aware of material, nonpublic information (defined below) about the Company or other companies. The Company’ s policy is applicable to all directors, executive officers, and employees, and prohibits trading and tipping others to trade, when you know material, nonpublic information. You will also be precluded from trading the Company’ s securities during certain periods as further described below. Rule 10b- 5 under the Securities and Exchange Act of 1934, in conjunction with Rule 10b5- 1, specifically addresses insider trading. Insider trading violations are pursued vigorously by the Securities and Exchange Commission (the “ SEC ”) and the Office of the Attorney General of the United States. Penalties for insider trading violations include civil fines of up to three times the profit gain or loss avoided by the trading, criminal fines of up to \$ 1 million and imprisonment for up to 10 years. There may also be liability to those damaged by the trading. While the regulatory authorities concentrate their efforts on the individuals who trade or who tip inside information to others who trade, the federal securities laws also impose potential liability on companies and other “ controlling persons ” if they fail to take reasonable steps to prevent insider trading by the Company’ s personnel. A company whose employee violates the insider trading prohibitions may be liable for a civil fine of up to the greater of \$ 1 million or three times the profit gain or loss avoided as a result of the employee’ s insider trading violation. The failure of any director, officer or employee to comply with the Company’ s policy on insider trading may also subject him or her to sanctions by the Company, including dismissal for cause, whether or not the failure to comply results in a violation of law. MicroVision has adopted this policy statement both to protect you and the Company against claims of insider trading and the severe consequences associated with the violations of the insider trading laws. This statement of policy is also intended to prevent improper conduct on the part of anyone employed by or associated with the Company and to stipulate when an insider may trade in the Company’ s securities.

**Material, Nonpublic Information** Material information is any information that a reasonable investor would consider important in making a decision to buy, hold or sell securities. Any information that could be expected to affect the Company’ s stock price, positively or negatively, is considered material. Information is considered nonpublic if the information has not been broadly disseminated to the public for a sufficient period to be reflected in the price of the security. The information must not only be publicly disclosed, there must also be adequate time for the market as a whole to digest the information. As a general rule, information should not be considered fully absorbed by the marketplace until after the second full business day following an announcement or disclosure to the marketplace via a press release or through a filing with the SEC. Some examples of material, nonpublic information are: • Financial information (i. e. projections of future earnings or losses, or other earnings guidance); • Earnings that are inconsistent with the consensus expectations of the investment community; • A pending or proposed merger, acquisition or tender offer; • A pending or proposed acquisition or disposition of a significant asset; • The development of a significant new product or process; • The gain or loss of a significant customer or supplier; • Significant legal, regulatory or legislative developments affecting the Company; • A change in senior management; • A change in dividend policy or the declaration of a stock split; • An offering of additional securities; and • The existence of liquidity problems or impending bankruptcy.

**Insiders** According to court interpretation of Rule 10b- 5, an “ insider ” is any director, officer or employee of the Company who possesses knowledge of material, nonpublic information about the Company and who has a duty to the Company to keep this information confidential. In addition, family members and friends of directors, officers or employees as well as professional advisors (i. e. accountants, attorneys, investment bankers and consultants) who receive material, nonpublic information about the Company may be considered “ temporary insiders ” of the Company. Statement of Policy It is the policy of the Company that no director, officer or other employee of the Company who is aware of material, nonpublic information relating to the Company may, directly or through family members or other persons or entities, (a) pass that information on to others outside the Company, including family and friends, (b) buy or sell securities of the Company (other than pursuant to a pre- approved trading plan complying with Rule 10b5- 1), or (c) engage in any other action to take personal advantage of that information. In addition, it is the policy of the Company that no director, officer or other employee of the Company who, in the course of working for the Company, learns of material, nonpublic information about a company with which the Company does business, (including a customer or supplier of the Company), may trade in that company’ s securities until the information becomes public or is no longer material. MicroVision Insider Trading Policy (2021) 2 Transactions that may be necessary or that may appear justifiable for independent reasons (such as the need to raise money for an emergency expenditure) are not exempted from the policy. The securities laws do not recognize such mitigating circumstances, and in any event, even the appearance of an improper transaction must be

avoided to preserve the Company's reputation for adhering to our high standards of conduct and ethical behavior.

**Disclosure of Material, Nonpublic Information** No director, officer, employee or agent may disclose material, nonpublic information about the Company unless authorized to do so by the Company's Chief Executive Officer or General Counsel. Only certain employees are authorized to disclose material, nonpublic information. Unless you are authorized by the Chief Executive Officer or the General Counsel, you should refrain from discussing material, nonpublic information with anyone not subject to this policy.

**Transactions by Family Members** This Statement of Policy also applies to your family members who reside with you, anyone else who lives in your household and any family members who do not live in your household but whose transactions in the Company's securities are directed by you or are subject to your influence or control (such as parents or children who consult with you before they trade in the Company's securities). You are responsible for the transactions of these other persons and therefore should make them aware of the need to confer with you before they trade in the Company's securities.

**Twenty-Two Hindsight** Before engaging in any transaction, you should carefully consider how enforcement authorities and others might view the transaction in hindsight.

**Quarterly Blackout Periods** The Company's announcement of its quarterly and annual financial results has the potential to have a material effect on the market for the Company's securities. Therefore, to avoid even the appearance of trading while aware of material, nonpublic information, all directors, officers, employees, and their family members, are prohibited from trading in the Company's securities during the period beginning two weeks before the last day of each fiscal quarter and fiscal year of the Company and ending after the first full business day following the Company's issuance of its quarterly or annual earnings release. Exceptions to this requirement are permitted only by the written approval of the General Counsel. However, no employee may buy or sell Company securities even during the window periods if he or she is in possession of material, nonpublic information.

**Hardship Exceptions** A person who is subject to a quarterly earnings blackout period and who has an unexpected and urgent need to sell the Company's stock in order to generate cash may, in appropriate circumstances, be permitted to sell the Company's stock even during the blackout period. Hardship exceptions may be granted only by the General Counsel and must be requested at least two business days in advance of the proposed trade. A hardship exception may be granted only if the General Counsel concludes that the Company's earnings information for the applicable quarter does not constitute material, nonpublic information. Under no circumstance will a hardship exception be granted if the applicant is in possession of material, nonpublic information.

**MicroVision Insider Trading Policy (2021)**

**3 Stock Option Plans** This Statement of Policy also applies to the exercise of an option to purchase stock if proceeds from the sale of Company stock are being used to pay the exercise price of such options in a so-called "cashless exercise."

**Post-Termination Transactions** This Statement of Policy continues to apply to your transactions in Company securities even after you have terminated employment or service with the Company. If you are in possession of material, nonpublic information when your employment terminates, you may not trade in the Company's securities until that information has become public or is no longer material.

**Additional Prohibited Transactions** The Company considers it improper and inappropriate for any director, officer or other employee of the Company to engage in speculative transactions in the Company's securities. It therefore is the Company's policy that directors, officers and other employees may not engage in any of the following transactions with respect to the Company's securities:

**Short Sales** A short sale is the sale of a security that one does not own but has borrowed in anticipation of making a profit by paying for it after its price has fallen. Short sales of the Company's securities portray an expectation on the part of the seller that the securities will decline in value and could signal to the market that the seller has no confidence in the Company or its short-term prospects. For these reasons, short sales of the Company's securities are prohibited by this Statement of Policy.

**Publicly Traded Options** A transaction in options is, in effect, a bet on the short-term movement of the Company's stock and therefore creates the appearance that an insider is trading based on inside information. Transactions in options also may focus the person's attention on short-term performance at the expense of the Company's long-term objectives. Accordingly, transactions in puts, calls or other derivative securities, on an exchange or in any other organized market, are prohibited by this Statement of Policy.

**Hedging Transactions** Certain forms of hedging, such as zero-cost collars and forward sale contracts, allow a stockholder to lock in much of the value of his or her stock holdings, often in exchange for all or part of the potential for upside appreciation in the stock. These transactions allow a person to continue to own the covered securities but without the full risks and rewards of ownership. When that occurs, he or she may no longer have the same objectives as the Company's other shareholders. Therefore the Company strongly discourages hedging transactions of the Company's securities. Any requests to engage in hedging transactions of the Company's stock must be submitted to the General Counsel (or the Board of Directors for the CEO, CFO and General Counsel) at least two business days in advance of the proposed transaction.

**Margin Accounts and Pledges** Securities held in a margin account may be sold without consent to meet a margin call. Similarly, securities pledged as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material, nonpublic information or otherwise is not permitted to trade in the Company's securities, directors, officers and other employees are prohibited from holding Company securities in a margin account or pledging Company securities as collateral for a loan, except to the Company. In the event that a director, officer or other employee has pledged the Company's securities as collateral for a loan as of the date of this Statement of Policy, then such person may request permission to continue to pledge Company securities for an existing loan or renewal or refinancing of such loan. In such event, the director, officer or other employee of the company must submit a request for approval to the General Counsel at least two weeks prior to the proposed execution of documents evidencing the proposed pledge.

**MicroVision Insider Trading Policy (2021)**

**4 Limit Orders** A limit order is a specific order that sets a specific period in time in which to buy securities at or below a specific maximum price or to sell securities above or at specific minimum price. The General

Counsel must approve any transaction using a limit order for the Company's securities. The General Counsel must review the effective period and timing of any limit order in advance of placing such an order. In general, limit orders will not be approved that begin before or extend after the trading window guidelines discussed above. Despite prior approval, you must cancel any limit order if you later learn material, nonpublic information before the execution of the trade. MicroVision's Assistance Any questions regarding this Statement of Policy or its application to any proposed transaction may be directed to the Company's General Counsel. Ultimately, however, the responsibility for adhering to this Statement of Policy and avoiding unlawful transactions rests with the individual director, officer, employee or other related parties that must comply with this policy. All directors, executive officers and employees must certify their understanding of and agree to comply with this Statement of Policy by signing the attached Certification. This Statement of Policy on Insider Trading may be amended by the Company from time to time, and a copy of this Statement of Policy on Insider Trading shall be posted on the Company's intranet or otherwise made available to those covered by it.

MicroVision Insider Trading Policy (2021) 5 INSIDER TRADING CERTIFICATION I certify that I have read and will comply with the MicroVision's Statement of Policy on Insider Trading as amended from time to time. I understand that the Company's General Counsel is available to answer any questions I have regarding the Statement. I will comply with the Statement of Policy on Insider Trading for as long as I am subject thereto. Signature: Print name: Date: MicroVision Insider Trading Policy (2021) 6 MicroVision Pre- Clearance Procedures MicroVision, Inc. (the "Company") has approved a Statement of Policy on Insider Trading relating to securities trades by all of the Company's directors, executive officers and employees. This document describes additional procedures that apply to directors, executive officers and those non- executive employees who regularly become aware of earnings information or other material, nonpublic information about the Company. The Company's Pre- Clearance Procedures have been established to: • help prevent violations of the federal securities laws and to avoid both the trading and the appearance of trading on inside information; • assist directors and executive officers in complying with their SEC filing obligations; and • help directors and executive officers avoid inadvertent "short swing" (i. e., six months) profit liability. These Pre- Clearance Procedures are applicable to (i) all directors, (ii) all executive officers and their administrative assistants, and (iii) all other persons who are informed by the General Counsel that they are subject to the Company's Pre- Clearance Procedures (each a "Company Insider"). No Company Insider may engage in any transaction in the Company's securities (including hedging transactions, transactions in derivative securities, gifts, contributions to a trust or similar transfers) at any time without first obtaining pre- clearance of the transaction from the General Counsel. A request for pre- clearance should be submitted to the General Counsel at least two business days in advance of the proposed transaction. Additionally, pre- clearance for the General Counsel will also require approval by the Chief Executive Officer; pre- clearance for the Chief Executive Officer, Chief Financial Officer and other Section 16 Officers will require approval by the Audit Committee Chair; pre- clearance for directors will require approval by the Board Chair and pre- clearance for the Board Chair requires approval of the Audit Committee Chair. Any Company Insider who wishes to implement, modify or terminate a trading plan under SEC Rule 10b5- 1 must first pre- clear the plan with the General Counsel. As required by Rule 10b5- 1, a Company Insider may enter into or modify a trading plan only when he or she is not in possession of material, nonpublic information. In addition, a Company Insider may not enter into or modify a trading plan during a blackout period. A trading plan is a pre- established plan that directs one's broker to buy or sell securities according to pre- established parameters. Transactions effected pursuant to a pre- cleared trading plan will not require further pre- clearance at the time of the transaction if the plan complies with Rule 10b5- 1 by specifying the dates, prices and amounts of the contemplated trades, or by establishing a formula for determining such dates, prices and amounts. Event Specific Blackout Periods In addition to the quarterly blackout periods described in the Company's Policy on Insider Trading, from time to time an event may occur that is material to the Company and is known only by some or all of the Company Insiders. As long as the event remains material and nonpublic, no Company Insider may trade in the Company's securities. The existence of an event- specific blackout period will not be announced, other than to those who are aware of the event giving rise to the blackout period. If, however, another Company Insider, requests permission to trade in the Company's securities during an event- specific blackout period, the General Counsel will inform the requester of the existence of a blackout period without disclosing the reason for the blackout period. Any person made aware of the existence of an event- specific blackout period should not disclose the existence of the blackout period to any other person. The failure of the General Counsel to designate a person as being subject to an event- specific blackout period will not relieve that person of the obligation not to trade while aware of material, nonpublic information.

Short- Swing Profit Transactions As described in the Company's Policy on Insider Trading, the Company considers it improper and inappropriate for any Company Insider or any other Company employee to engage in speculative transactions in the Company's securities. The Company expects each Company Insider who is subject to Section 16 of the Securities Exchange Act of 1934 and the rules thereunder to monitor his or her own compliance with such rules and to avoid entering into prohibited transactions or recognizing short- swing profits. The rules under Section 16 are complex, and Company Insiders should consult with the General Counsel or outside counsel prior to trading in the Company's securities in order to maintain compliance with those rules. In general, however, Section 16 prohibits short sales (i. e. a sale of stock that is not owned by the seller or a sale of stock where the seller does not deliver the stock within 20 days or deposit the stock in the mail within five days of the sale) by executive officers and directors. Section 16 also discourages directors and executive officers from engaging in short- term trading of the Company's securities, because such short- term trading may focus Company Insiders on the Company's short- term stock market performance instead of the Company's long- term business objectives. Section 16 provides that a Company Insider must disclose to the Company any profits made on short- term transactions in the Company's securities. A trade will be considered short-

term if a Company director or executive officer buys or sells a Company security and offsets that transaction within six months of the original transaction date. For example, a short-term trade would occur if a person buys shares in January and then sells shares before June or conversely the person sells shares in January and then buys shares before June. With limited exceptions, any such matched transactions within a six-month window that give rise to profits will be subject to disgorgement. Any shareholder of the Company, including members of the public, may insist on the Company's right to enforce such disgorgement. MicroVision Pre-Clearance Policy 20212 A Company Insider who is aware of material, nonpublic information when he or she terminates service as a Company Insider, may not trade in the Company's securities until that information has become public or is no longer material. In all other respects, the Pre-Clearance Procedures set forth in this document will cease to apply to a Company Insider upon the later of (i) such Company Insider's termination of service to the Company or (ii) expiration of any blackout period in effect at the time of such termination of service. Company Assistance Any questions regarding this memorandum or its application to any proposed transaction should be directed to the Company's General Counsel. All Company Insiders must certify their understanding of and agreement to comply with the Company's Pre-Clearance Procedures set forth in this document, by signing the attached Certification. These Pre-Clearance Procedures may be amended by the Company from time to time, and a copy of these Pre-Clearance Procedures shall be posted on the Company's intranet or otherwise be made available to those covered by these Procedures. MicroVision Pre-Clearance Policy 20213 PRE-CLEARANCE PROCEDURES CERTIFICATION I certify that I have read and will comply with the MicroVision's Pre-Clearance Procedures as amended from time to time. I understand that the Company's General Counsel is available to answer any questions I have regarding this policy. I will comply with the Company's Pre-Clearance Procedures for as long as I am subject thereto. MicroVision Pre-Clearance Policy 20214 Exhibit 21. 1 LIST OF SUBSIDIARIES Subsidiaries of the Registrant as of December 31, 2024 Jurisdiction of Organization MicroVision GmbH Germany Exhibit 23. 1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-265489, No. 333-184701, No. 333-173114, No. 333-163929, No. 333-19011, No. 333-71373, No. 333-42276, No. 333-45534, No. 333-73652, No. 333-89176, No. 333-141458 and No. 333-249418) and on Form S-3 (No. 333-184703, No. 333-184702, No. 333-182462, No. 333-175419, No. 333-160577, No. 333-228113, No. 333-253145, No. 333-272616 and No. 333-282840) of MicroVision, Inc. of our report dated March 26, 2025, relating to the consolidated financial statements of MicroVision, Inc. appearing in this Annual Report (Form 10-K) for the year ended December 31, 2024. /s/ Moss Adams LLP March 26, 2025 Exhibit 31. 1 CERTIFICATION PURSUANT TO RULE 13a-14 (a) and 15d-14 (a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Sumit Sharma, certify that: 1. I have reviewed this annual report on Form 10-K for the period ended December 31, 2024 of MicroVision, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15 (f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: March 26, 2025 /s/ Sumit Sharma Sumit Sharma Chief Executive Officer Exhibit 31. 2 I, Anubhav Verma, certify that: Date: March 26, 2025 /s/ Anubhav Verma Anubhav Verma Chief Financial Officer Exhibit 32. 1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U. S. C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of MicroVision, Inc. (the "Company") on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Sumit Sharma, Chief Executive Officer of the Company, certify, pursuant to 18 U. S. C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 (15 U. S. C. 78m or 78o (d)); and 2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: March 26, 2025 / s / Sumit Sharma Sumit Sharma Chief Executive Officer Exhibit 32. 2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U. S. C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES- OXLEY ACT OF 2002 In connection with the Annual Report of MicroVision, Inc. (the “ Company ”) on Form 10- K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “ Report ”), I, Anubhav Verma, Chief Financial Officer of the Company, certify, pursuant to 18 U. S. C. § 1350, as adopted pursuant to § 906 of the Sarbanes- Oxley Act of 2002, that: Date: March 26, 2025 / s / Anubhav Verma Anubhav Verma Chief Financial Officer